{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.1",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System",
      "version": "1.0.0",
      "authors": "Esther Wollert and Charles Tapley Hoyt",
      "description": ""
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/73ec5665b99a7a4b84edd84bbd46b34fac335358/external/mesh-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"
    },
    "namespace_pattern": {
      "PUBCHEM": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_list": {},
    "path": "/Users/cthoyt/dev/hbp-knowledge/hbp_knowledge/dani2007.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "1,1-dimethyl-4-phenylpiperazinium iodide",
      "id": "f6a683e1c97873337d3e8873ac2e002d60e709bec9d176f2b04e7e0ef15abd652928fdda1bb91a8103329c55b0f03b623db2b3ef3ee31a9f602c638fae446643"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methyl-3-isoxazolyl)urea",
      "id": "059e301c877f4e7ca32bf349000c28379627fb6d8f14ef5c5af14d66b0c2cf33aa7d607793e587becc85a58e38a8f7d6532c869fff5a8b4c477dd8713918ac45"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "5-hydroxyindole",
      "id": "15678421d73bfa9b41f63a21c042e69d55dd1ae8a03d8ccade85be7c8e592b34452551220d74eae6651b627d767ff488328ca32cea6bef0aa51d9f6cfb50da80"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "EC 3.1.1.7 (acetylcholinesterase) inhibitor",
      "id": "f5115583612f3f2c40ebc54f2c528dbe7732517483538bd78de15d36df42904885a4fb82e5b4feac53e21bbdcf5c7e8e78c1985c4ff40c3fe99509119cf8984b"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta polypeptide 42",
      "id": "c2da54109c90719396dfdfb558be74582b8522863849a50f3f5029b7d60f4d53df3cfa1a97b787e760a2f74ea1f74012eb49273beeded42a2873d788953b4a13"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta",
      "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "calcium(2+)",
      "id": "4fb8648e4c5fea95cea6a46291d28175bba677d8b6fa8d607b1febef51c8370cbc1ff98d09312dc418ff31d04177d26f231d4f0a1a963f43fbc29cfb3269d3c9"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "dihydro-beta-erythroidine",
      "id": "3a8b2ffd4458387e74d5f02ef30a62008752f3a9f6df74e15207700ffd3106b29ace5c879daa5ebc9f2e97f81acb84c94b7c782b0088d8262d7bac0b05aa00eb"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "gamma-aminobutyric acid",
      "id": "9583f9418a889245078b43a5744b3aee37f76bff3bff369f21f4091c2ad475d69415b09ff3b3b7e7aa6014f4e5dab6706477099218ce8a665f6751daba94e6b3"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "glutamate(2-)",
      "id": "9749d43ec7dd166b90348b70de96bca3f824fa7c4624aa5f0d82f2dbd2e1d559cccd5b7e74c86268f2e152cea542c1a7c99fc9b98d5d12853d44f9a56b615e4a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "nicotinic acetylcholine receptor agonist",
      "id": "fc6fb75f41a3ae25bcce72b6848a0a4ca5f3c45b495a894c7b278d2851f4a07a201fb7402153571cbcf47dafbab3240d324f4b208bd81d15241ae2c9a4a3d037"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "nicotinic antagonist",
      "id": "d1caeb325e913183b2325afe5926c6ce845f30526b3d3730b45f5e8f91ef6c9d32adfe9308baf887d627d85d6060884cd36721c3f3982d78566d0217e8142641"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "Mecamylamine",
      "id": "f81a5cca79277a3483157d6067c10b7916d6c4e183c85db0a42f5f427ebe2280a46a47f3899a13dfa89025b0f2b6dd3a0b02b3240d27c1c06be3d4a662516041"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "acetate",
      "id": "d5ded90176d5afa9f66d7ba0409d88511fae64124dd5180c6295d21039a13c0acfa4ca0169c04feb91a4195659923665085980b3745f5473e1b4e88b5c54686f"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "acetylcholine",
      "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "choline",
      "id": "88fb57fa667be5fcf348ed86cb041de48401b10103512c286ebe600483744af962b0f34c7d2f8cfb57af6f72aaab29d8787cb64de2aa5d58ecd6fe01876d0cee"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "dopamine",
      "id": "70f7314679db5bae3c2260b6feff9a6ef3407fb6a585f92a58c59fd066a2ec279c0091a72edba3465c4f2aa033afff7fded0b16c4a84f4bbcecd092a934ea66e"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "galanthamine",
      "id": "829d639ffa1b9cf0dc884553079510b093dde8971a129c58afff24ea1d1103f0db214945577b66dc941db450715ecdfe7951a8498afafb02cb1653b60845fc57"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "genistein",
      "id": "06c0c5690741680b20f26d0526d1f231e119a814ce6a1ac4f064c9c9b504b737f1df6ef95c231dd40aa4b6b02e91df3dacbc2aa1c419c1ca588e49458be812c8"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "ivermectin",
      "id": "425cd27f63098087def92425120f8f729312418a6f6c22e82e76430603b753ab7fbec5dd986b502d2aadbdf25e27b2e87b0456baaf052a58345fef840d27e185"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "nicotine",
      "id": "81813864e07e0e955a0ccf7e9ec2430ce5cdbeae237c18991897f8314b29bdb2d0985dedfa71377ab67541fbcea0567e323d0cf47a5517efc83a67ac442abdb8"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "noradrenaline",
      "id": "4553f1e4c5c615e68013cac87f15df1fff14c0afbce0727cddfcb8329488f1dbcb9f1fd9b88f78d222bb7b5cc67d2c05a5e1fad860c45047b0fac2778cb1ffac"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "serotonin",
      "id": "8d7ceea95cec905de8941facf48d632e3c509b6ce451f835af1fab5789daacc5bbf8d1bdb7cfd90863a70871a9a9a07b093896248712aa6567895ae8cf3b3502"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "tetrodotoxin",
      "id": "65ff5ae406d6e963f8eac8f110d32940794a53654a5b943a5631476e4e64e4750a1891f2da393a1c47160cdbea5c4470bbe17ba19d9d733939c837a162d762fc"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta aggregates",
      "id": "1d739f6eba3532950fc068e81f7aea675ce76d42a049b5a301ad8bccf2f503d6c2a79c9d417d4d35cc760c340b5db2513536b3c420156a92bda3605be3537740"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Cations, Divalent",
      "id": "f74ea6c1477c452d747029aefa3495b78604ddc4e0a373ac5248ce824f66e4adede2ae855c872ccec253ade35077f70ddd2cd7d02bf12f97a091d70bce55ddb5"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Cations, Monovalent",
      "id": "8256d0b8abd40e1cbf74a33140661c8a3da9c09d05d44b42a1577dd041eb3c4bc5fcc4dbddc6cf0462c23ccaf725a34d791d4f7d80935db9b7eb971c46c9961c"
    },
    {
      "function": "Abundance",
      "namespace": "PUBCHEM",
      "name": "5311278",
      "id": "ff81d119cda1e470274cf159ad465f21316788516511107a8bb3ff4710f153ea6b47866648d59fba863fec885bb7d4cbaebf7ae31c0c7790cfabaf04c4f3b108"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "action potential",
      "id": "901de59afa5ace673f840a9280c6c4e90e0a29149ecc6f22eb89eb6b2552b02db6bb21b6c5ca1f9521fe529ffe4150c0bb7b4bcdf6fb426bb21c3c745a6fc163"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "circadian sleep/wake cycle, REM sleep",
      "id": "994160c96a6d0ac2b178e9fbda9b705b8870dc8ac9b6068100d1cc74a25655738da752866b230c4c34f9e4ff3750c8730949f8c41326959a4bcead720bdfd355"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "circadian sleep/wake cycle, wakefulness",
      "id": "659916040322ba15c17593b501f3d790aaad20d01dde6b053c834ecfbb41db18f47b02b80317a599481273428af365f8af6950b34b737bc1ab08e8c2a061a777"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "depolarization of postsynaptic membrane",
      "id": "787acb6c32e84595052378c2e731ce850cba5d2b0b5cb5243be8f9b0c1f9405494fbfc78f4ebdde328fe3d29992eb5bf9fac0d634a8c4d86f8dbca8ba87f4a17"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "developmental process",
      "id": "2d58f3e43d1ffd870565a3ac3fd98a577b6517155ea6f78aff60dc2808ce7b998c0318655b4eb2ff7793be79f5d87335d72e1569ef95640efa758e8a46cb007c"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "long term synaptic depression",
      "id": "04ec49ad6b4da8e5c99f70ba9166bb5be4375b6c18ded88a0b534bb9efb674a4fc29df2db0fdff22fb2f30c0e11f18263dbd5170cdb80a4aa5df1b3ca825c523"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "long-term synaptic potentiation",
      "id": "90aca567c87981f32f4001b6386423cf473ef52decf04004bd136ab80fd9088c2698b76c8baf740f8e282b107790d3c88130dc99225bab73b22516859dc4203a"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "membrane depolarization",
      "id": "e39ac862551cfbabee553faf7cdf77b10d143e9ff3adb94c30b29266575efc988ceb9f023c9c3092ce7eb4f4f002154cd839d4a358db03ef35e2da80ced957f5"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neuron death",
      "id": "ad7c90f2bc746a5118759fd1c8857478c02207d574a26faaac9d6e4d6fa4661d8d87446139db0024a4011aae26027d3cabdfba663aec0ac0a8242868efb81dcd"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neuron remodeling",
      "id": "c59b4214cb0ff2e3aaeb04b51be25a31edbc3745addfe9f7cfc856c72971bb19266f6bf70f49841a4a7c6f322d6726e8263ec124d9b1f97116dd39ad0ea52f89"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neurotransmitter secretion",
      "id": "1cf91e4476702328465b4b541ae95b24860d781268fc1cb5e5da2e588e6597c2326a5d3fc6ae09cba9d63f72e66b01352a7598d5cd01869ee200041796a6bb79"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "regulation of action potential firing pattern",
      "id": "0e7e17a743c48e5722044139cbc96da6e3288d725b6272375548ccb9f451d59d0a00eab720aa49589197949acc4acc94d4a0d9bf54e0bbdfaa5cc6084f7767b9"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "regulation of action potential firing rate",
      "id": "da754bb18bac18ff82a4c78aadcbdf0960abd83d2121c6a1b9d70d500b8c49d953ea4fe86d3001e751d4d79d04ef6857fa756a27dd75193259bf0b99090cba13"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "regulation of synaptic plasticity",
      "id": "903846a9cf9209815f6dcfe040df50ed6f55896865a72567e9c38cd2dcf71773d60453fcfefaf38dc2933bb0c524d73f2b9c10afe99231cbd86c56860a8197da"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "response to pain",
      "id": "723a8339e33d3bc86298aadd7745afa0a5cc8c863f92e77363d18c8dd4790825444d6f9683049cb67b3a523e1c2934ff28d0a6b6d6cc639c6a41d08176cadbe7"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "rhythmic excitation",
      "id": "8220bd770fd75a674fa0e7b826bbb174dba9a51672ded33ff55a85aa02e7495883cf4e588095da655f79e533dd7746bbef562ef6cba6b6e68344dcb5a0321180"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "synaptic transmission, cholinergic",
      "id": "4238cec14ccdcd7b90d308eb0687f5775f5b1ed79362c1d84004721894a52040968a92b357a6bf971a144e903a9b441d8be9ba5ee78e5e039c5f83c167933575"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "synaptic transmission, glutamatergic",
      "id": "68a9f5219c953044883133bf5f935c2f9a074b8e719aa33dc0766bba8dd98b92cefd134205b93bd6f586b594e1438d307a554c9771bccd03dc6acf03e09bb82c"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "cognition",
      "id": "8d73f2caa1c473289d5f37cbdd4ad391a120cdbdf2356b373070c2a7b2bc0c785eaa620782fa2dd947c666100f0a169e81f35864f359cadf3e1550962fcc4127"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "learning",
      "id": "24fec79fe31de63921d3028dd6ce5e335372d8d221877724830f05136d6c879daa7585768231b87272f0ebb8a7f6038f1aabb8785a626cca0c95b33018cc1633"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "memory",
      "id": "87795d00588bdf77d28229ad379d58f00922f6339902a803d0672cc15e669269f8fe50785b2851e1e82046f4e1e49920534ec68c0b6911bea5a1b838dbc999cd"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "GABA-A receptor complex",
      "id": "a08498a131b15415e8e3963d3be2cc4ae087964e77a5ed2a84cd2ea4170b0186162ab8b3fa62b30f2b9e05edc7b565815afe588ee0b7b5008e620d8c1cd9c2bf"
    },
    {
      "function": "Complex",
      "namespace": "GO",
      "name": "voltage-gated calcium channel complex",
      "id": "d0bd03457b2391b76e8b194527084f7dbda9afb086056b41fd2fd578a214bc68e95a6036acadff2869300766d8b8f88d0e1c416f9779ce6ccf7a131448a67e1a"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta polypeptide 42",
          "id": "c2da54109c90719396dfdfb558be74582b8522863849a50f3f5029b7d60f4d53df3cfa1a97b787e760a2f74ea1f74012eb49273beeded42a2873d788953b4a13"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA7",
          "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
        }
      ],
      "id": "ab6cedf236d6ad4b8cee1a22790e2b7bd0bb91318b164f8f5f63f286d85092af61c50e9e28b4f267b5212d7be34f722310822347de4682466026066eb6ce4d61"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "1,1-dimethyl-4-phenylpiperazinium iodide",
          "id": "f6a683e1c97873337d3e8873ac2e002d60e709bec9d176f2b04e7e0ef15abd652928fdda1bb91a8103329c55b0f03b623db2b3ef3ee31a9f602c638fae446643"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "ivermectin",
          "id": "425cd27f63098087def92425120f8f729312418a6f6c22e82e76430603b753ab7fbec5dd986b502d2aadbdf25e27b2e87b0456baaf052a58345fef840d27e185"
        }
      ],
      "id": "746da9df2d9e01ea7ab6636573defd3d9ed2624f7779f1a211d5541cc48102844cde1f54a33767cbcabe043a2f817b20b717b4fc46efe1902f655ce3dc100300"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "5-hydroxyindole",
          "id": "15678421d73bfa9b41f63a21c042e69d55dd1ae8a03d8ccade85be7c8e592b34452551220d74eae6651b627d767ff488328ca32cea6bef0aa51d9f6cfb50da80"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "acetylcholine",
          "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
        }
      ],
      "id": "19dfc7a4dfbe378d201706f5e4aa25a431668a4bff59dfd4d63e11afe895ae699e6b2f4c6b353e9bce6dd6355f2ca8f4a59f70e6af7cc59ed357149769bceb7d"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "acetylcholine",
          "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "ivermectin",
          "id": "425cd27f63098087def92425120f8f729312418a6f6c22e82e76430603b753ab7fbec5dd986b502d2aadbdf25e27b2e87b0456baaf052a58345fef840d27e185"
        }
      ],
      "id": "296e1f023bf3e0efaad6e08f263c51e4c78337ca75a162ae3785c250a1c9ea18d140b7fb1ae64a15013fcb6943b14a88d562b4eb3bc72f7e44fb586aa63e2214"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "CHRNA4",
      "id": "e1e479226a67e190a74a68d36e1d14a9e471b87407adee5c90aaf4a844534e333eeb4074503fb6b551bb9309cb995461ea60e6c00e08b5eae96c613bf4ebc413"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "CHRNA4",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "?"
        }
      ],
      "id": "dda305d3eca9355a62cbd608ed4a63ef1d55d9ee598fe06596999baff58edf4cee994c58cc3cb2015e00a5c99a2edd3107699bbc1e57d676d5642e02381e4d86"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "CHRNB2",
      "id": "5622fd830925a6531d48fb668c953c765dffa8a1547f9696b4d8dd7f30e81846ec1c2f6ef31e23bbb62f09f2b3e681e7de84dad6771c741e34cc4518f530b080"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "CHRNB2",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "?"
        }
      ],
      "id": "11193d193c0a2083e608cee008d82831983dbffb2e996569f9ac0956d8181bcecfb749b55e6a1060a73e0327f838f5a31a3e07531d58a5d6f418f33af84b16ec"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CHRM",
      "id": "594a3d51d68645c1c7bd415d714cdd5ffbd7f3f1810061ac498dfe67dd6b2cdf0416d9cd0ccb4e0c91e5ffa93ca34eed8f06b38f2651821a6325f4c41e30e1ba"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CHRN",
      "id": "2d70e5187bc44ed8ee9d64163e62e209522d576460d28ee8c947c1bda63c6d1f2233f349d74a2bae45ed4d59044c0e1be1f56ea9944bc08740426eb8678d6df5"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "SRC",
      "id": "4ea062912ca937b208eb598b751fe8d2aa93ee78f5667d30e9137ff6b5f6022d36137d01c4ab78a629959de097f7df5424826be4b1f30c7e8f8c2be04817670a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ACHE",
      "id": "9d3104b5d47c472fac8109aed790de48a5955d80c72a1ca46580350b0d6c41e96ee75cb1cb868657d107abf241c10c81b1c892d4eee5a68f558f78cd14ca802f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA4",
      "id": "c49a9652cba613af55ca7c03c108df12ef9ea4e37760fcb7b2302e019899a0eaa11f06c1dcd9b9eb143b9baba0daa89737d73dafbfde9d8ddd8dd53b2a8269e0"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA4",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Ser248Thr"
        }
      ],
      "id": "bc0a3db39c10e0a8f0d2d91cb940d6385c513e8a56478926b6b2fa1b5a52e1883ad8e34485ae769457dabfaafa395713a4c82867e3c5de67843eac6e51b2825b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA7",
      "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA7",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "a037fee9be64a6370d2311be3bf74e73f6bf8d3c27809de3b4478b4bdd3b2dc1289c0ece6ec7468683693e9da4653fb2823d09bf6a9adcea81b37c4038f40e7d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA7",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Leu254Thr"
        }
      ],
      "id": "c62bc542c9a32cc583073959e976786d34227a904e76e099b47345ff74f977e3c6bc15c6f018ad3e8e5744fa1717355a7495e086a85ccd1cafa7cb85e0e184e8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA7",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Leu255Thr"
        }
      ],
      "id": "b16fd1dafb2eae4d8e8c591a7591c23b0edde9d326b5ec915108ee192c536bd759e4f6e75b44cebdfdc9c623ad38bc288ea25ba510fd61973f3a51d6ce083af1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB2",
      "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "HBP",
            "name": "hyperphosphorylation"
          }
        }
      ],
      "id": "ede67fb639f29861d91976fefa16d8279b53ae13a659f35d70ed12e01bf3f339ffcf701fc54c7c4e908fee9902c02aac3e0022dcae5a7afa217ed2d4dba133b0"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Alzheimer Disease",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Autistic Disorder",
      "id": "41227c3ac66efa97a24eb6d03cb177d54a431fa51585630d90e232f11a4df549741dc765dab38fce12819d5b4543c339f3faa834b3bf53d46df1f7c09d827fb0"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Autosomal Dominant Nocturnal Frontal Lobe Epilepsy",
      "id": "b77a297b0e3d998613ce53451c7b5b84caacd4f3dc3b929d9cdfade8109cc6ec3396c1dc05c8d16c5c64486792a1286af521eccdd530457d28b9238bbebcaa02"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Behavior, Addictive",
      "id": "43e66698b879a871a66e11ad5a6226b99bd6bb6336b009cf4b2207b4ff96a4ddc04900e2589974a679ce296a12dd2f705c220addd477024be5a16602f788298f"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Down Syndrome",
      "id": "3c70bf952a4a541caab3c832e97814c7d87b5c568cc2225ad985dab51802bf5d41c75c20298514df6338380b564189e309d158ae0b7d7729e949a13e9d0f024c"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Lewy Body Disease",
      "id": "96e3a681a3c1aae0a3a2b158907153fc5e976e52d355cfecb0af2b5ab767bda982ed8c11b147dcfb04800986cc50e61613c751e724d8259e7863ae31adfd78f1"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Parkinson Disease",
      "id": "d7f039170f83b3fcc27595412f3b0352cd1fe95f8481a2b1144ce311ac81bb5f0087a0a7e682f498d193e00b8e8fb29908a6e0b8e23da5ef349aeeb4723b9be0"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Anxiety",
      "id": "28f6f3390e4ae722f1c1298abe2059a3e03a8a2de93e506a747733d9e980ed28bb2feb1074ec430fda167d3f38e3c1d930e10c16e5e04f371938ce866caba0dc"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Arousal",
      "id": "6ef612dbaaa09cdc75717ac036d0e0e14c676f92570b19ba659e80dcd0d16f2b523447f2efad61138c062bc54b2b0b71746373d1b6cb093174bf13a46624f27c"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Attention",
      "id": "67735e2aaf2e17459a41794138aa7720fd27fb15a51cb7f34b74132b92accef7585efb2a338de3ca85bd2a5ae6bc4f7aac672d1a06b2e19c5e45400ba7b94036"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Depression",
      "id": "1db8d744eac9b5ac408852b1889bb0b09e0054ea091932f1aa44aeeab0ea1b3825912c55c72fb2d25d5848e77d62b1c6a1df2063a2f25ae03e5ca30085922799"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Epilepsy",
      "id": "309287b0127e543335c9af55c3e86d48efd9edc5986c0b2b003993d599ad1265556f61abfbbf374e7d73a2cfdf66edb8363ca959d460752bb82144ea8760a90a"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Schizophrenia",
      "id": "574fcb4e3970e1cefa6d4d88a96a5c535f41ece9b53fe0a456e4f7aeb388900e1d66e72e024e1f50c0892640dc2faae2adb82b00a4c66c9aeec93db08dc4a136"
    },
    {
      "function": "Reaction",
      "reactants": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "acetylcholine",
          "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
        }
      ],
      "products": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "acetate",
          "id": "d5ded90176d5afa9f66d7ba0409d88511fae64124dd5180c6295d21039a13c0acfa4ca0169c04feb91a4195659923665085980b3745f5473e1b4e88b5c54686f"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "choline",
          "id": "88fb57fa667be5fcf348ed86cb041de48401b10103512c286ebe600483744af962b0f34c7d2f8cfb57af6f72aaab29d8787cb64de2aa5d58ecd6fe01876d0cee"
        }
      ],
      "id": "ecc251bc346f68dfb6e1f0399d0b3f1ef4cea53f93d67532489ed66c29c326b854fd1ccf38ddd6923d9a3323e1f475b7590ab54136537a9383c13c6d127254fe"
    }
  ],
  "links": [
    {
      "line": 62,
      "relation": "increases",
      "evidence": "Presynaptic and preterminal nicotinic receptors enhance neurotransmitter release, and postsynaptic and nonsynaptic nAChRs mediate excitation as well as activity-dependent modulation of circuits and intracellular enzymatic processes. ",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Presynaptic Terminals": true
        }
      },
      "source": 60,
      "target": 38,
      "key": "a8dea36c463fdeb8eb20798a94c662951c858112f0bd65c7dc6c2d920eace9f3bb84c7b87680955d9c9f22f0199cbf829340da3a051c5946cd6850c61d3f8db0"
    },
    {
      "line": 147,
      "relation": "increases",
      "evidence": "Activation of presynaptic nAChRs increases the release of many different neurotransmitters (1, 2, 4, 5, 40, 41, 77–83).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Presynaptic Terminals": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 38,
      "key": "a3e5a1e389af8e18a600f01ba3c56abc230d05ef98b783795adc6349e4ade944158a5040678c444e2c03795018b0bc74fdc702276c0940a30044575e374d53fd"
    },
    {
      "line": 202,
      "relation": "increases",
      "evidence": "Presynaptic and preterminal nAChRs increase the release of neurotransmitters in the hippocampus, particularly the main neurotransmitters, GABA and glutamate (41, 78, 81, 97).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Presynaptic Terminals": true,
          "Hippocampus": true
        }
      },
      "source": 60,
      "target": 38,
      "key": "6c352fc2a7d498950a52133cf829b309e5721b2bb91f5c320be72c55e0f557b048a3e3482313a334003127e2bad2a87c14af3d4634856465b0ac47e40e299ef5"
    },
    {
      "line": 65,
      "relation": "regulates",
      "evidence": "Presynaptic and preterminal nicotinic receptors enhance neurotransmitter release, and postsynaptic and nonsynaptic nAChRs mediate excitation as well as activity-dependent modulation of circuits and intracellular enzymatic processes. ",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 43,
      "key": "8d962881daf723ef0432d2617912495e277b0c6a63c2ed156d7ef8a7f36a596ca9ee846e4d2894122f843ba85645a90700b65b3a33783d2872d4a15f7fd0259f"
    },
    {
      "line": 196,
      "relation": "regulates",
      "evidence": "Furthermore, by directly exciting or by shunting the progress of an action potential at a bifurcation, axonal or dendritic nAChRs alter the spread of neuronal excitation.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "MeSHAnatomy": {
          "Dendrites": true,
          "Axons": true
        }
      },
      "source": 60,
      "target": 43,
      "key": "65bce09746360994eaea224aff6aab62d857c7fe9bd90253c82560ab3d9c2bb1fe08994d7ad2500a6754e5272dda70ff9fc7325a746978a24279c15ae753f41f"
    },
    {
      "line": 66,
      "relation": "regulates",
      "evidence": "Presynaptic and preterminal nicotinic receptors enhance neurotransmitter release, and postsynaptic and nonsynaptic nAChRs mediate excitation as well as activity-dependent modulation of circuits and intracellular enzymatic processes. ",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 37,
      "key": "e2901639f238e1a38dcad83e14338e09061fbf6b8327a20304c995d292a6c272640c366ddc7ba10b66eaaad5bbb9e6623783d36a73c6cbc429543b90c6a7356b"
    },
    {
      "line": 69,
      "relation": "association",
      "evidence": "By modulating activity-dependent events, nAChRs participate in fundamental aspects of synaptic plasticity that are involved in attention, learning, memory, and development (3, 12–16).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 41,
      "key": "ca3c958b48d5e37a0bf4524346e2a068a0538c0fc1a4d1a2e44fd9832607e6eb6fbb7651586f4876324ee601bbaf3437aa5ab103ee8aba44f165afb9062b48fd"
    },
    {
      "line": 178,
      "relation": "increases",
      "evidence": "Nicotinic stimulation enhances glutamate release on multiple timescales, extending from seconds to a few minutes (81), and contributes to the induction of synaptic plasticity (4, 13, 14, 16, 88).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 41,
      "key": "edbc5a3963fbf3036ccc7a47da90be62eee3b0806eee09227daf4b2248b24df0f6712b658357f17b8b14aaad46e76867a81d6f49d0e31656ba3bc4d5b9736020"
    },
    {
      "line": 222,
      "relation": "association",
      "evidence": "Nicotinic receptors also modulate glutamatergic synaptic plasticity.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Cell": {
          "glutamatergic neuron": true
        }
      },
      "source": 60,
      "target": 41,
      "key": "cdd983d95ea29e62fd0fabe52ce0c789dd7feb79e4f252a02f1d2f8642f4941caa12464ab04b66ce30dd31d686ce1e34230261b04502107495669511a7e29e73"
    },
    {
      "line": 70,
      "relation": "association",
      "evidence": "By modulating activity-dependent events, nAChRs participate in fundamental aspects of synaptic plasticity that are involved in attention, learning, memory, and development (3, 12–16).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 81,
      "key": "961352cd7fd05b1fddee295f4346ee1849c383919a71924387bca051c59e6a459ea24e7c9840e2b9442a229165d30603a33901616ff85e23af6d4a5caa5a2215"
    },
    {
      "line": 71,
      "relation": "association",
      "evidence": "By modulating activity-dependent events, nAChRs participate in fundamental aspects of synaptic plasticity that are involved in attention, learning, memory, and development (3, 12–16).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 47,
      "key": "96f3274aa9ded8426a2002c4fabf2e9506b2630a197c1ed9d022585b8b0160d39446cd22ca4dec2a8a2cf1b51675580d4924734276485abadff1fae834f46dd4"
    },
    {
      "line": 72,
      "relation": "association",
      "evidence": "By modulating activity-dependent events, nAChRs participate in fundamental aspects of synaptic plasticity that are involved in attention, learning, memory, and development (3, 12–16).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 48,
      "key": "9074eb9bab2038e49d751805371833e3d2a347c93fd31a9b0ec6f45957a5d03af69f36f2809a70c0387de43933b7dde8d81556efcffe2100764368cda017083e"
    },
    {
      "line": 73,
      "relation": "association",
      "evidence": "By modulating activity-dependent events, nAChRs participate in fundamental aspects of synaptic plasticity that are involved in attention, learning, memory, and development (3, 12–16).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 32,
      "key": "020b7e02cb563e263bb3f209cfdd55349117884df179ba2aeacbd874c300716e4270f4a9aa8d0fd8b4d119798234f6c2247085aefaef832ff1ccd87bcfc3e527"
    },
    {
      "line": 76,
      "relation": "association",
      "evidence": "Decline, disruption, or alterations of nicotinic cholinergic mechanisms have been implicated in various dysfunctions, such as schizophrenia, epilepsy, autism, Alzheimer’s disease (AD), and addiction (17–23).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 84,
      "key": "a9b30676728bdbc002823f38eed4580d3ad43c2580188c8c154e7e1a624eff95fa15d5d6cf026f45a3db482c4fd1555404b46c2ccdc742e96a42a67b764b491b"
    },
    {
      "line": 293,
      "relation": "association",
      "evidence": "Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 84,
      "key": "e6f92e421decda2fa188c839d2c0977bc227ec029218a8e6c0fa866786476e592559348306b2db3241e165ed9bef9830312109ed045a7f5349feb68fa77add31"
    },
    {
      "line": 77,
      "relation": "association",
      "evidence": "Decline, disruption, or alterations of nicotinic cholinergic mechanisms have been implicated in various dysfunctions, such as schizophrenia, epilepsy, autism, Alzheimer’s disease (AD), and addiction (17–23).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 83,
      "key": "3920640eebcadae987dc97cf5fed9ffb5603859567132f9bfdbb86075e21d5d325d99da038871307d593a90737114cfc996633f063e71c2b4c94fc16056121f8"
    },
    {
      "line": 292,
      "relation": "association",
      "evidence": "Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 83,
      "key": "6b9bdabfa4737082ab1ed5d0cb4ba35c9378168529767eacfc7db7ae14a0efdf68e6d8d1e616672514f7212de8502a0149a337fb7c29baa675da7d3ab9d884e6"
    },
    {
      "line": 78,
      "relation": "association",
      "evidence": "Decline, disruption, or alterations of nicotinic cholinergic mechanisms have been implicated in various dysfunctions, such as schizophrenia, epilepsy, autism, Alzheimer’s disease (AD), and addiction (17–23).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 73,
      "key": "19a69aa78b2a8e41753e911c059fd797ee0cccacf287084f65722729d5412821d5b453630bc21ecaaa0b2f2c2f795bbed9184e4328210d2398acc74da752be1f"
    },
    {
      "line": 283,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 73,
      "key": "24d17afa1b57e6a254898bd370b17e295a972dd3ed793b942c1e79784c3da9dd57732c7abf3cbd05a4157ea0c4234222556a596bc16db9517a9d3da6d8ce7a65"
    },
    {
      "line": 288,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 73,
      "key": "a0aec93ee2d2a20143822683830b55b7b29867dab7049bac28241ad1ab7ad551afcaefe5aa6d358c85c91799673991d2a3abfda00a11dba15fed418b059ccae9"
    },
    {
      "line": 79,
      "relation": "association",
      "evidence": "Decline, disruption, or alterations of nicotinic cholinergic mechanisms have been implicated in various dysfunctions, such as schizophrenia, epilepsy, autism, Alzheimer’s disease (AD), and addiction (17–23).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 72,
      "key": "a0a90c1d9f43436e950b44a964206a5fd500d7a1299eda99259d0be30db8d54841d7d1d25f003201b9731fa946a3b6cc00b098f66f4443c6699e0c362e06f63e"
    },
    {
      "line": 280,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 72,
      "key": "68afed9d9cf63506d4c657558745d7deac391128e82d80de72cb290aac9020dde67e0af01dc889847ed63e01e4628065d0604c21fd61193f28152695d43e74be"
    },
    {
      "line": 285,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 72,
      "key": "d92d20a1ffb4eafd5b64a3e5e467573ee07e3e628af123f6b8e3f7f1413a26fb68b25addf0ea85a7aa10358c7343659eda5071ba9c931a747b6e02f1d37c9833"
    },
    {
      "line": 333,
      "relation": "negativeCorrelation",
      "evidence": "As AD worsens, cholinergic neurons are progressively lost and the number of nAChRs declines, particularly in the hippocampus and cortex (140, 158).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "Cell": {
          "cholinergic neuron": true
        }
      },
      "source": 60,
      "target": 72,
      "key": "d19e2afb03a891acf2085d38b2a9be3e8ef5ed7633e349d6ed932aef9f66e25d64f052e9b3fcc54e16594bd77a98d39214a6289e4b2a10cd8278c51a3933433f"
    },
    {
      "line": 80,
      "relation": "association",
      "evidence": "Decline, disruption, or alterations of nicotinic cholinergic mechanisms have been implicated in various dysfunctions, such as schizophrenia, epilepsy, autism, Alzheimer’s disease (AD), and addiction (17–23).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 75,
      "key": "e40c8523bab5c198befdd5836d1835e0d29c4d12ada0db55e1bd51c3c8c46c1b5fa579423cfce3a93ca9340be2029482181ae8f145674915cd0920ecb9e88c73"
    },
    {
      "line": 83,
      "relation": "increases",
      "evidence": "Mammalian nAChRs are cation selective, being permeable to small monovalent and divalent cations.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          }
        }
      },
      "source": 60,
      "target": 26,
      "key": "34a7af9763f23e98a76734ad6f6ee04d7546a3466f838105ed7002461ccfd50bf9f8f3c4bfaa5bdf2440791decec17b498c4b457b4d80843a65b0aa22c34bc12"
    },
    {
      "line": 84,
      "relation": "increases",
      "evidence": "Mammalian nAChRs are cation selective, being permeable to small monovalent and divalent cations.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          }
        }
      },
      "source": 60,
      "target": 26,
      "key": "43015e1b293a13fd1839608f7a2ccde4c29f87791b2f579c4862275ba021029bcdde4ea6f32ef445b87893af88f8346bfbab41d8cf54e4a9f3465fe3d16becdb"
    },
    {
      "line": 85,
      "relation": "increases",
      "evidence": "Mammalian nAChRs are cation selective, being permeable to small monovalent and divalent cations.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          }
        }
      },
      "source": 60,
      "target": 25,
      "key": "11eb6d69caef622cca3d4d3a39de97c1fbe717e97c128b0d5516d8489db4d897ddc584e40938485aa0f89d375f6187e8e8c2ff6b45243cdaf4a2912d2c64c809"
    },
    {
      "line": 86,
      "relation": "increases",
      "evidence": "Mammalian nAChRs are cation selective, being permeable to small monovalent and divalent cations.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          }
        }
      },
      "source": 60,
      "target": 25,
      "key": "5e433c5f820df4ec193d811d59fe7c933ffb1d1372c57cf55b5e3f6ed2dc06f70a5a2d5391befcc44a675c333432541ae6588cca1282388be374e0a8969e45ec"
    },
    {
      "line": 91,
      "relation": "increases",
      "evidence": "Nicotinic receptor activity causes depolarization, and the divalent cation perme- ability plays an important physiological role by supplying ionic signals, including calcium (39–41).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 35,
      "key": "02450266ffe5bd6ded2ba0d6372825d946229150c3beeaa90d0625b003683516c7d64668e209616b5a894c5ac3a58b0bc14f53c662047387c1b40b16954d3e92"
    },
    {
      "line": 172,
      "relation": "increases",
      "evidence": "In addition, nAChR activity produces a depolarization that activates voltage-gated calcium channels in the presynaptic terminal (87). ",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Presynaptic Terminals": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 35,
      "key": "5af15cef8982d88dbcfd69d167d3c722a414a5fd9035c97a83ae33fd765e0d5abc82150aab00829d356ac18572f6e7c5296006566f11ffdfcaacd17a6eb56e4e"
    },
    {
      "line": 231,
      "relation": "increases",
      "evidence": "Activation of nAChRs on distal apical dendrites depolarizes the cell and promotes action potential ﬁring",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Dendrites": true,
          "Neocortex": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 35,
      "key": "291dcbf8a0d7f5df6c70503ff210129f971c8432896eb8570459bcd172458549e5519c73a0e3823fe749ecc4073bbc4e07c0633ad628d57a7e656889e28aebd4"
    },
    {
      "line": 165,
      "relation": "increases",
      "evidence": "Nicotinic receptors mediate a small direct calcium inﬂux (42–44, 85).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          }
        }
      },
      "source": 60,
      "target": 6,
      "key": "c5aa747102bf8e8a9b6626f09cdd5c4c349b9329e4834979172f4f4709c818f1d74a0f603256a4d17f53285eac49ad4eb4b5802a12a97fe3641d25fbdd7afc54"
    },
    {
      "line": 177,
      "relation": "increases",
      "evidence": "Nicotinic stimulation enhances glutamate release on multiple timescales, extending from seconds to a few minutes (81), and contributes to the induction of synaptic plasticity (4, 13, 14, 16, 88).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 60,
      "target": 9,
      "key": "9520719a3ffaace53fd02c03e6b6d9113516bbbd4d2f780d3513ec1813bd43ce10ba401348faa76bc3e86d514184ded61195095277aadd0b62d076afaa07ce24"
    },
    {
      "line": 204,
      "relation": "increases",
      "evidence": "Presynaptic and preterminal nAChRs increase the release of neurotransmitters in the hippocampus, particularly the main neurotransmitters, GABA and glutamate (41, 78, 81, 97).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Presynaptic Terminals": true,
          "Hippocampus": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 60,
      "target": 9,
      "key": "28e6102494c5dea5c536daec10253f35f07b6cabff832b75092823a057fbd8889991445e9b256f609d2c9dfae44f1856f643c4ef0d8f2fa9b277deb7a37846b1"
    },
    {
      "line": 203,
      "relation": "increases",
      "evidence": "Presynaptic and preterminal nAChRs increase the release of neurotransmitters in the hippocampus, particularly the main neurotransmitters, GABA and glutamate (41, 78, 81, 97).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Presynaptic Terminals": true,
          "Hippocampus": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 60,
      "target": 8,
      "key": "842ebbb3254f0567470f0f84eb57219d839f675a182c47f170bfd91b6fe1b5311387d988227231e559eea13fa5ddcb9b3c6609aec1de523c114e560db602fa93"
    },
    {
      "line": 216,
      "relation": "regulates",
      "evidence": "In the rat CA3 region, spontaneous activation of GABA A receptors produces giant depolarizing potentials, whose frequency is controlled by α7∗ and non-α7 nAChRs.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 49,
      "key": "91d9924a7013a1bd664ab7a8d8f5457e07a64bb02e2fe66160bb080666dc04277366c53efe80a896c1c5bf1c0a83e1b24e70ace56ca0e4dacaf692c2a7612e56"
    },
    {
      "line": 227,
      "relation": "increases",
      "evidence": "Activation and desensitization of nAChRs by bath-applied nicotine also increases LTD induced by a stimulus train",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 33,
      "key": "19c6fdc62be01c511be8a9529360b210399f9ade841c999251016fcbb400bf56827b226d42c205bf496e00101b91598ca737ee59260c66a82ec7c0d3a163062f"
    },
    {
      "line": 232,
      "relation": "increases",
      "evidence": "Activation of nAChRs on distal apical dendrites depolarizes the cell and promotes action potential ﬁring",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Dendrites": true,
          "Neocortex": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 40,
      "key": "259c6fc48711cff4f32f290243b2a5a4323818d7684f0f9558daa8bbe0530a4952ab2fb0c8e6ded1ccd12c38686afb900405b61d3558b76dd8ccff53fa6aee08"
    },
    {
      "line": 237,
      "relation": "association",
      "evidence": "Acting through these excitatory and inhibitory inputs and nAChRs located on the DA neurons, nicotinic receptors inﬂuence the ﬁring modes and ﬁring frequency of DA neurons (119, 121).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Dendrites": true,
          "Neocortex": true
        },
        "Cell": {
          "midbrain dopaminergic neuron": true
        }
      },
      "source": 60,
      "target": 40,
      "key": "97959f487d7b0f244c35f82957d25146c495679585e5be0059aa30037928592123336040dacf32399a23084cb6a27f24807bfdfe888473c9c8e146548de73c8d"
    },
    {
      "line": 252,
      "relation": "increases",
      "evidence": "The nicotine initially activates nAChRs on DA neurons, causing an increase in burst ﬁring and overall ﬁring rate (88, 121, 123, 124, 134).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Cell": {
          "dopaminergic neuron": true
        }
      },
      "source": 60,
      "target": 40,
      "key": "8d1c5c3082599e7584d271cffd26a55b9f9321717dff99fc1beec9e8202d20e5353626da4a5d4d94dc58fc2ea4225798ecaf0bce7465f71256935346c215e8bc"
    },
    {
      "line": 238,
      "relation": "association",
      "evidence": "Acting through these excitatory and inhibitory inputs and nAChRs located on the DA neurons, nicotinic receptors inﬂuence the ﬁring modes and ﬁring frequency of DA neurons (119, 121).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Dendrites": true,
          "Neocortex": true
        },
        "Cell": {
          "midbrain dopaminergic neuron": true
        }
      },
      "source": 60,
      "target": 39,
      "key": "66e584502b5eaa28f27490a185f1cd454aa8ab85b3a03d8db7842f534ed75cb56297cb854e6256e5a77d455f0cfda8a290893fac3b3f830fdddee75bbdced242"
    },
    {
      "line": 281,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 77,
      "key": "60705298692292faf23f55c75e47f8dde095aa567436233f1cc522571ba41415ec2e14b8832c1974e741fe939e6286da4ca4563c55c3ee23b1399a08a1e4381b"
    },
    {
      "line": 286,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 77,
      "key": "c8e08959ac129285fc73c40b9d08800dbe2a0b63c6b6fa54c92068db70023e29fcdd1c7b83cf84e7daf9aa7891c707358a5cdd71c6320d5402e8b8b1aff8ea5a"
    },
    {
      "line": 282,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 76,
      "key": "f3f99e0246051c6b0f06dc835c2fc9b750f4dc8ec01c5c89d2944965467f039a4b9f20dca4083c6fab78e92ab85bb159ed86c4f65494e5675b1163353f133430"
    },
    {
      "line": 287,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 76,
      "key": "57d09264a0d663e5207307c9fdfe21bce60df72390410801d6716b9ea4fb750fe483403b1d886c57c7e55a5d5da9172af532ac724d8ba1d5e37c1ea415f2dc74"
    },
    {
      "line": 284,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 78,
      "key": "b7c8260c61a5fb77671849356c74be9936936dfb693052c71bb3a58b0b6e8de70443df13c9d449ed948b757e82b1846ff63e814245635991947e20ae926d8d4f"
    },
    {
      "line": 289,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 78,
      "key": "5679a245f40d144c4f5d865b76881dbe72357b2a34caa074d03e125eb696663bdcf26ffd6263b280507ad9a0a63657d902af0110dc2b97f695cdae48ea2bd0ef"
    },
    {
      "line": 294,
      "relation": "association",
      "evidence": "Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 42,
      "key": "da96457c709a5f418ee916c7b3ad61f0438e971e712fd8e6b5b4328da7177aeb824c9ec1e642e1d84443ed910808791af132bef1c3bac9bf744b894f4d7c7c1f"
    },
    {
      "line": 295,
      "relation": "association",
      "evidence": "Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 79,
      "key": "39b50d0d25419069d52aaca142bc0609faadd39e5e4fe1f9ed64e0bee5cbd227773b2811aa46277f882086f0092c0231786fe55a4be72c53dc88589455b32a63"
    },
    {
      "line": 296,
      "relation": "association",
      "evidence": "Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 60,
      "target": 82,
      "key": "317b6bcff92ba2001b791d6f7485b60982da1dde0630018834d1751a01c7ff33f0235bf360e89b1670564705c04309aebda140908c6023399dca859ab4617519"
    },
    {
      "line": 384,
      "relation": "increases",
      "evidence": " Moreover, although nicotine increases wakefulness in wild-type mice, it does not affect β2−/− mice. Overall, stimulation of nAChRs promotes arousal and REM sleep.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Epilepsy": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 80,
      "key": "9a4676e7ac4886182993af3006cfb7ae270a913e18a151711a1267d27e1d6ae6a52c1254130d09968c5681f96342395422af0280f7464e5fef12f5328fecb52e"
    },
    {
      "line": 385,
      "relation": "increases",
      "evidence": " Moreover, although nicotine increases wakefulness in wild-type mice, it does not affect β2−/− mice. Overall, stimulation of nAChRs promotes arousal and REM sleep.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Epilepsy": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 60,
      "target": 29,
      "key": "c9e764b0f8e4e782ce5d46e4d7f5f83b48278f98c1eae539f2cfd2a0f079ee583a6eb9c9691bbdce458bfdd574b038ff721addf6fd588c1cfd7a82ac35a42d7c"
    },
    {
      "line": 69,
      "relation": "association",
      "evidence": "By modulating activity-dependent events, nAChRs participate in fundamental aspects of synaptic plasticity that are involved in attention, learning, memory, and development (3, 12–16).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 41,
      "target": 60,
      "key": "356585257034dd1999bc9ec43ca583be75b7a479c6c4d07a1ac241d14fb10970a46e68d0565e21b787ac864965da1b8f4d25c5bd06961c8589739a84407f571f"
    },
    {
      "line": 222,
      "relation": "association",
      "evidence": "Nicotinic receptors also modulate glutamatergic synaptic plasticity.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Cell": {
          "glutamatergic neuron": true
        }
      },
      "source": 41,
      "target": 60,
      "key": "40af680a6eec3c63415c7bf22f24237c385c871b189f34ab23a32122da052f35081ca39522e7386c821a76f6482c1a4c7bdc9abaaca3e73087226cb96ca5a0d4"
    },
    {
      "line": 70,
      "relation": "association",
      "evidence": "By modulating activity-dependent events, nAChRs participate in fundamental aspects of synaptic plasticity that are involved in attention, learning, memory, and development (3, 12–16).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 81,
      "target": 60,
      "key": "69b93e922007df25f3420af898cf3413dcb5fa2d176e6c5f3dc396a9732283e0707f804ed0a87c96fc93eed75fcbc6768f391f96bb9f42da207c1c111f962e99"
    },
    {
      "line": 71,
      "relation": "association",
      "evidence": "By modulating activity-dependent events, nAChRs participate in fundamental aspects of synaptic plasticity that are involved in attention, learning, memory, and development (3, 12–16).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 47,
      "target": 60,
      "key": "ec40de5ef9e6ecbbd1f57fcdfcaf0f61db803a9b99d287aa0cac5c510a58b7e672cca911583eda132fbafaeda2a732b399f229909d8841f680a6707044cdc9b9"
    },
    {
      "line": 72,
      "relation": "association",
      "evidence": "By modulating activity-dependent events, nAChRs participate in fundamental aspects of synaptic plasticity that are involved in attention, learning, memory, and development (3, 12–16).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 48,
      "target": 60,
      "key": "a7f859117a91b62c764b39f156a158e57902c47d668ea8df75d701f9c9bbbb43c04110e320c153729a90502819c90ac38bfb0c969a3d1911748319013194be5c"
    },
    {
      "line": 73,
      "relation": "association",
      "evidence": "By modulating activity-dependent events, nAChRs participate in fundamental aspects of synaptic plasticity that are involved in attention, learning, memory, and development (3, 12–16).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 32,
      "target": 60,
      "key": "350e5502bef6e98697a395764774ef6fffd49c854432a718694f89c0989ce3c702366810142bc586c09f7ca8c4124b2e5082343694e857a802a11199d676da0c"
    },
    {
      "line": 76,
      "relation": "association",
      "evidence": "Decline, disruption, or alterations of nicotinic cholinergic mechanisms have been implicated in various dysfunctions, such as schizophrenia, epilepsy, autism, Alzheimer’s disease (AD), and addiction (17–23).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 84,
      "target": 60,
      "key": "cd001528637650694d0dca15f31a6e1cc24123481644d3093c7cddee6b5da10fd6017ba9d6a83026c726d40ff4de8395c5af9ab533fddfb7840c9b8b70c4d212"
    },
    {
      "line": 293,
      "relation": "association",
      "evidence": "Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 84,
      "target": 60,
      "key": "56e119fa7d4f93b1d9c3641e556c3d736b0be7733c3f941e5b074ff8c7d56508cb476bc1de44b47a205e632980653145606b1d6f0946472e41044f60fbd0320d"
    },
    {
      "line": 77,
      "relation": "association",
      "evidence": "Decline, disruption, or alterations of nicotinic cholinergic mechanisms have been implicated in various dysfunctions, such as schizophrenia, epilepsy, autism, Alzheimer’s disease (AD), and addiction (17–23).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 83,
      "target": 60,
      "key": "08d03a714f2206903e86f357142807295c9b4f0f4f87fbf601e50d20614aeee5d833c9190ce53da2504955c76267d75cce26050473af0c6d0640946353e8143d"
    },
    {
      "line": 292,
      "relation": "association",
      "evidence": "Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 83,
      "target": 60,
      "key": "253aad3660eb2a604a2ad6bf61c6365eaad43b547488761509eeabb8b182969c6a793d5d80839e21f66276c809f880f8b3806a0bff6bcb41f2a6ba55512687fd"
    },
    {
      "line": 78,
      "relation": "association",
      "evidence": "Decline, disruption, or alterations of nicotinic cholinergic mechanisms have been implicated in various dysfunctions, such as schizophrenia, epilepsy, autism, Alzheimer’s disease (AD), and addiction (17–23).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 73,
      "target": 60,
      "key": "e0bad5ef3e43d7a7a3fab5da8ca405bf4bf9f29e9721fe3b3cd39bf79f9804d02f1905e1ef25e67751553735cc3679e613d425b390432df5e47332fac0a9f59d"
    },
    {
      "line": 283,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 73,
      "target": 60,
      "key": "31cd665044c44d3aa2e872cbbc2d9512492cca036af1d747f9de20cb508ec23cf3cc423a9ec0407ed3a4bb53d4308f76794da2e3c97e3aa941608327621e58b1"
    },
    {
      "line": 288,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 73,
      "target": 60,
      "key": "ef89bae514e09d6c45388808cb930e2c757b95b707699d24889484ae3da4acaa434d2c34e6eea0cfd497b62180deddf4ab6634cb8e02e6d6142007d625c5e9c9"
    },
    {
      "line": 79,
      "relation": "association",
      "evidence": "Decline, disruption, or alterations of nicotinic cholinergic mechanisms have been implicated in various dysfunctions, such as schizophrenia, epilepsy, autism, Alzheimer’s disease (AD), and addiction (17–23).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 72,
      "target": 60,
      "key": "dabe9ef297623a6da5020b9fd26eadbeb9c44ba6af2e24b665424e43e2200b6a6f1312e56548f58ed4131f36f812df916475c88f88192248c1147281693de108"
    },
    {
      "line": 280,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 72,
      "target": 60,
      "key": "4d903cc75cb6512aa79c24bb5839fbc86adbaab51cac9f5c0e9c3625c8718c94afb1f5b93a7ec0a46a33a2e01ff8e217a76f5852d3077349d595e9ed20a688b1"
    },
    {
      "line": 285,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 72,
      "target": 60,
      "key": "0590d54c0e2dfe2088778161089e0a0e9545731288a8be1feed6bbba4b633a6897c7c6149803b1fb9dcd9f5c692976ae4f845ef3872fbb06fb1611c8b24533aa"
    },
    {
      "line": 333,
      "relation": "negativeCorrelation",
      "evidence": "As AD worsens, cholinergic neurons are progressively lost and the number of nAChRs declines, particularly in the hippocampus and cortex (140, 158).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "Cell": {
          "cholinergic neuron": true
        }
      },
      "source": 72,
      "target": 60,
      "key": "f4916035cf671ba22fbd93c0d3453aa8e02c91d4f7e782adc415aac84b80d037a579a928deb2ed78b8468dcd45e6fc4de66e5e4a9826e06ef4ee7774e55f18a3"
    },
    {
      "line": 326,
      "relation": "positiveCorrelation",
      "evidence": "The most well-appreciated neuronal loss, however, is in the cholinergic system (155, 156), particularly the basal forebrain cholinergic system comprised of the medial septal nucleus, the horizontal and vertical diagonal bands of Broca, and the nucleus basalis of Meynert (157).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Cell": {
          "cholinergic neuron": true
        }
      },
      "source": 72,
      "target": 36,
      "key": "4fe08dc9662f13fc20a9a22c8bf0dde11e3c3a1496e0c54ceb13105d07545b06afba8907a7408facf6fec1d47e9742202e3e8f032cf585516895cd90dbaaf36e"
    },
    {
      "line": 332,
      "relation": "positiveCorrelation",
      "evidence": "As AD worsens, cholinergic neurons are progressively lost and the number of nAChRs declines, particularly in the hippocampus and cortex (140, 158).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "Cell": {
          "cholinergic neuron": true
        }
      },
      "source": 72,
      "target": 36,
      "key": "92f0b2021f43ba27467d2a3c10d91877bfb07437f5099c28350ae17f511f6dc25a19d3fafedf0909a221ca347795c7d6be85ef026ac07e87156f3c222c771ffd"
    },
    {
      "line": 354,
      "relation": "association",
      "evidence": "Although Aβ peptides negatively alter the cholinergic system at multiple sites, including ACh synthesis, ACh release, and muscarinic receptors (157), the discovery that Aβ1−42 binds to α7 nAChRs with high afﬁnity suggested the potential for a causal role of nAChRs in AD (159, 160).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 72,
      "target": 51,
      "key": "8c3c985cb0d5b0f7f2ec5643ac73987aca80310770ca10b670a94575f990b060e420065b8f25f5082e692dd164932a18244d9cc65dc995777562b9b5e4b0570f"
    },
    {
      "line": 80,
      "relation": "association",
      "evidence": "Decline, disruption, or alterations of nicotinic cholinergic mechanisms have been implicated in various dysfunctions, such as schizophrenia, epilepsy, autism, Alzheimer’s disease (AD), and addiction (17–23).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 75,
      "target": 60,
      "key": "ec88c35d90268906c8b644dabdb91c46a5563d615116238466903988e5ec9857247cbfebcadc083e16a6c456e7bc48ef827a812b14faf4316e27bc46bcb943e7"
    },
    {
      "line": 173,
      "relation": "increases",
      "evidence": "In addition, nAChR activity produces a depolarization that activates voltage-gated calcium channels in the presynaptic terminal (87). ",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Presynaptic Terminals": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 35,
      "target": 50,
      "key": "a232c28f2639df8b99b1ad4c8e596115d20d119b9b6f56b7e7eb5f2d767334063bcb665edc874459e8091e5afa0f25e376a1919966a651c85a576a67bb24708f"
    },
    {
      "line": 94,
      "relation": "decreases",
      "evidence": "Similarly, replacement of the α7 leucine at the synaptic, extracellular end (position 254 or 255) of the pore by threonine dramatically reduced the calcium permeability of the α7 receptors.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          }
        }
      },
      "source": 67,
      "target": 6,
      "key": "5ff8d335829fda0979c2d19ebb0bb418013e33653aaffd0ca3b09ef074dadd8b84e3c597cdd64ad84c900fd93b0cc0fdb17960f90f51b1de6e1d824726eeac43"
    },
    {
      "line": 95,
      "relation": "decreases",
      "evidence": "Similarly, replacement of the α7 leucine at the synaptic, extracellular end (position 254 or 255) of the pore by threonine dramatically reduced the calcium permeability of the α7 receptors.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          }
        }
      },
      "source": 67,
      "target": 6,
      "key": "38b33ccc27564f71b941b5093e9a0568a0310274b039aeb1c924f37151bc07e0cf049e987af57ca5ca8eed704627c0f2cedaa6e96dee9ccf8e07b11e3e159878"
    },
    {
      "relation": "hasVariant",
      "source": 65,
      "target": 67,
      "key": "c692797d4ed79efc60a2aad7222943c91cc7e9a94c0959330651c84313dcd4c4fc618cb0d0000bc76e8d0199d73e9ae9ef75963e3003718e72c9e6b1a82662c0"
    },
    {
      "relation": "hasVariant",
      "source": 65,
      "target": 68,
      "key": "669909bc726171b1dfc7b0458c7a6749be13d62bb6645d9eee32288062ed30a3157f783bdc84bac41ff1a8b0b9e74287db1841def84a56bd68151c79ff492043"
    },
    {
      "relation": "hasVariant",
      "source": 65,
      "target": 66,
      "key": "9cf78bdc60acf0572b2fd9b1260cf3bbbbb646ee101d9c035c84306ff201a5843be65774345a9d35ba51384bb321b2d84d356bf8261c88ced53ff3bf68f2ebae"
    },
    {
      "line": 181,
      "relation": "increases",
      "evidence": "In some cases, the highly calcium-permeable α7-containing (α7∗) nAChRs mediate the increased release of neurotransmitter, but in other cases different nAChR subtypes are involved.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 65,
      "target": 38,
      "key": "36470fc784dda1c8aa0c35c15c7b26135492ef6dec289987dfd8ec9c08e23b67de866a7bc1fcd67d21e9f1519e3ae8ac14cdc2bb627e5284095540fc1db9b75e"
    },
    {
      "line": 186,
      "relation": "increases",
      "evidence": "Preterminal nAChRs located before the presynaptic terminal bouton indirectly affect neurotransmitter release by activating voltage-gated channels and, potentially, initiating action potentials (78, 91, 93).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 50,
      "key": "3a23a3554ed0bf81a13206421fa96b781454a9d3436df3e870b71ffaf971971236839b20241263be6f6bf4d1041ac0503671ee39ba213a8864695be62a76227d"
    },
    {
      "line": 260,
      "relation": "increases",
      "evidence": "Simultaneously, nicotine activates presynaptic α7∗ nAChRs, boosting glutamatergic synaptic transmission onto DA neurons (23, 88, 123, 134).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Cell": {
          "dopaminergic neuron": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 45,
      "key": "b1668930d24328f638f9a3512b642156211c217a9db6943cb7b5624120ee0ae5b51d8b8027d453119fa35a990209e2c598a634260d490c716a554dd36c6792ae"
    },
    {
      "line": 269,
      "relation": "increases",
      "evidence": "Postsynaptic β2∗ nAChRs initially depolarize DA neurons, causing them to ﬁre action potentials while presynaptic α7∗ nAChRs boost glutamate release. ",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Cell": {
          "dopaminergic neuron": true
        },
        "MeSHAnatomy": {
          "Presynaptic Terminals": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 65,
      "target": 9,
      "key": "9030c2c3a705784e1c5ee4aef97fc4dbe9c0dab633eb13041c0d2110a47739098eac8b434b7d75bd13bd0d436be0baf9f69990d12e8e1f47c03f8435a67220a5"
    },
    {
      "line": 357,
      "relation": "association",
      "evidence": "This prospect was supported by the finding that α7 nAChRs were found in plaques (159), and α7 and α4 subunits positively correlated with neurons that accumulated Aβ and hyperphosphorylated tau in AD brain tissue (161).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 65,
      "target": 24,
      "key": "a5a5efbcb295261c6875e0bf10f15300cbe32e7fef1138424c291118b3852a2bc08c2b791eef4c0c03a41c804d7df81f8d6c3d6e32e58e3b7a6210f1d1e1aded"
    },
    {
      "line": 360,
      "relation": "positiveCorrelation",
      "evidence": "This prospect was supported by the finding that α7 nAChRs were found in plaques (159), and α7 and α4 subunits positively correlated with neurons that accumulated Aβ and hyperphosphorylated tau in AD brain tissue (161).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Cell": {
          "neuron": true
        }
      },
      "source": 65,
      "target": 5,
      "key": "36cd7e385a870652d61e61b3c385d55dbadd7c87674813309ef5dffcea7a454e97cfe95dda87b6b5ffd740ea9e7cf6624498f627ba7ce3e819de6600527f14cd"
    },
    {
      "line": 361,
      "relation": "positiveCorrelation",
      "evidence": "This prospect was supported by the finding that α7 nAChRs were found in plaques (159), and α7 and α4 subunits positively correlated with neurons that accumulated Aβ and hyperphosphorylated tau in AD brain tissue (161).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Cell": {
          "neuron": true
        }
      },
      "source": 65,
      "target": 71,
      "key": "3d304cb93fb78b05cfda89976e8e994ead49993be43ca30a0d1400a7f378ff1e34fa6f708b0bba50993241a95bd419187bfcc03da1d83ac5f1eb68c697aba9ab"
    },
    {
      "line": 168,
      "relation": "increases",
      "evidence": "This calcium inﬂux can trigger calcium-induced calcium release from intracellular stores (86).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          }
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "cytosol"
          }
        }
      },
      "source": 6,
      "target": 6,
      "key": "4728b7bf93444e5b4607afd5f608e37d95e8031663a0bd54bff7d7f48aee16701da450beca57d9805a1923587cb71ab87fb00149681dff2cc69cf304c638d923"
    },
    {
      "line": 96,
      "relation": "decreases",
      "evidence": "Similarly, replacement of the α7 leucine at the synaptic, extracellular end (position 254 or 255) of the pore by threonine dramatically reduced the calcium permeability of the α7 receptors.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          }
        }
      },
      "source": 68,
      "target": 6,
      "key": "9736956e8a656eff5aad2f16d5408c06e46abb359cb6e2f649a27b8f6a006377a15d39ddb5b177618c1c8f0b6bc051c2efb250511d41691a3c98eaab58202ad2"
    },
    {
      "line": 97,
      "relation": "decreases",
      "evidence": "Similarly, replacement of the α7 leucine at the synaptic, extracellular end (position 254 or 255) of the pore by threonine dramatically reduced the calcium permeability of the α7 receptors.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "MESH",
            "name": "Intracellular Space"
          },
          "toLoc": {
            "namespace": "MESH",
            "name": "Extracellular Space"
          }
        }
      },
      "source": 68,
      "target": 6,
      "key": "544cbfc845b85606aee7ea921223183980543990152f3b3f8d64cb10da7ab620b45c0b055cac1ccf536a9950b3e235d42d22adf84c934f9b23cd2771f2c3e690"
    },
    {
      "line": 100,
      "relation": "directlyIncreases",
      "evidence": "Unlike many neurotransmitter signals that are shaped by pumps that return the transmitter to the intracellular space, the spread of ACh from the release site is determined by diffusion and by acetylcholinesterase (AChE) hydrolysis of ACh.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "pep",
          "namespace": "bel"
        }
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 62,
      "target": 14,
      "key": "e7472bd01f97db9d51cc1c65b2be56e458993ae0c41072c69247a91a1725055f6798db07516e61b29af47de8aa17e90b2e16b4360b88d7858f940b0a2cea8e80"
    },
    {
      "line": 109,
      "relation": "directlyIncreases",
      "evidence": "Another important aspect of this diffusive ACh signal is that its eventual hydrolysis creates choline, which also activates and desensitizes nAChRs in a subtype-selective manner (54, 55).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "pep",
          "namespace": "bel"
        }
      },
      "source": 62,
      "target": 85,
      "key": "b2934a2f3f69d13861e623eecb3fbaa3f2244c2182394f452e23b84c770af8e9baaffe936eb9fbfbe7000aedbf973edc548444a5ff0842a9a17da493468810ec"
    },
    {
      "line": 101,
      "relation": "decreases",
      "evidence": "Unlike many neurotransmitter signals that are shaped by pumps that return the transmitter to the intracellular space, the spread of ACh from the release site is determined by diffusion and by acetylcholinesterase (AChE) hydrolysis of ACh.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "subject": {
        "modifier": "Degradation"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 14,
      "target": 14,
      "key": "a3e0a67d785ee8d2008207a72bddd1a15b012e0a48af3c6e0179a7fcd6935a9a239a28007acccf17834b914a2c4f50ce15fff74c5515580e7ea8546584060513"
    },
    {
      "line": 113,
      "relation": "increases",
      "evidence": "The α7 nAChR has a relatively low afﬁnity for ACh activation, with an effective dose for half-activation at approximately 200 μM ACh.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 14,
      "target": 65,
      "key": "820cdc07f44dc3d4107f2525e60725b2e00116b9915121d78ac5591599007a4de997533c2c63a805df25b22874bfe4d83f3d350d5c76bab3c26347f8f7dac065"
    },
    {
      "line": 209,
      "relation": "increases",
      "evidence": "In most cases, the exogenously applied ACh caused action potential ﬁring by the GABA neuron that consequently regulated the activity of nearby pyramidal neurons (100, 103).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "GABAergic Neurons": true
        }
      },
      "source": 14,
      "target": 40,
      "key": "b30d0fcdbe3603a52bb5d1035986607bca117ce17ade30341264403ccd06c6a932b71343dbf92c6418e538495e83b1f7a532f012f5d8c23d4b7dd68f3fbd123d"
    },
    {
      "line": 104,
      "relation": "increases",
      "evidence": "Cholinergic volume transmission enables ACh to diffuse and to act at lower concentrations some distance away from the release site.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 44,
      "target": 14,
      "key": "c5bfa78fb5dba546e06068e89667e76e2148feda9c2ba0f43a95b38a6ffdbf640f1793eab6488e3e43c9e36e120980e5ee5279819cd9be2e2bf1ec3f4110fb4c"
    },
    {
      "relation": "hasReactant",
      "source": 85,
      "target": 14,
      "key": "8fa8aaa5b29aa56c106b1fdb243fed0b0c01276c1a22e7ff74cbcc1e0646ed2edfb7623455745142dcf387afa90a3d9a6963c69614017443f5a2bb5b50e8ce79"
    },
    {
      "relation": "hasProduct",
      "source": 85,
      "target": 13,
      "key": "9f7f1f3543540f275d2f8baa7ab4095849858e13cdd631d7bf04c761bbd3c1d4c2bb9e350c1c84ff2ab1bc004a33aed57a87e2713e5cf867b5cd8d5dad335a34"
    },
    {
      "relation": "hasProduct",
      "source": 85,
      "target": 15,
      "key": "047f68ef276dda59a670e84550acbf50d53018921a51fe8237537d0fb5860e861927eae3563e63a07201c0b33906f4e0c8be4d67f898ddadd52769a225e52082"
    },
    {
      "line": 110,
      "relation": "increases",
      "evidence": "Another important aspect of this diffusive ACh signal is that its eventual hydrolysis creates choline, which also activates and desensitizes nAChRs in a subtype-selective manner (54, 55).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 15,
      "target": 60,
      "key": "3c5e5a07250193960b4b5a99de964f7ce755e7013251290638202b20d1f516ac4e030114886cc61e2e48998b714d2fcc3c6231ad4cddd7b2808035988c9c8f8f"
    },
    {
      "relation": "hasComponent",
      "source": 54,
      "target": 14,
      "key": "530245085378de4831e32eca2fbd229bde7e2a686c4a2399a9b455bde3c786d20d204f9c42d02c4301c566521ecd6c465210a328430a6f96a44fdd89c4eb0062"
    },
    {
      "relation": "hasComponent",
      "source": 54,
      "target": 19,
      "key": "312dd8e8b8a8f124f908b7ee6246d52fbf4c046e3a20d83a1ca9f916a3f1a688d6630dab9aa62312696ec943350cc15fd7f9a0516f4e6c7aa8611a69dc49df84"
    },
    {
      "line": 116,
      "relation": "increases",
      "evidence": "For example, ivermectin increases the apparent ACh afﬁnity, the slope of the dose-response curve, and the amplitude of nAChR responses (68).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 54,
      "target": 60,
      "key": "a50ae775102eb201edce3863f8b459f6c4a5780a7a12525240f8f84e8267cc37d77f81a4bca2ebda5b3d83fec5f073ef52c13f04294297c1c6f0b8d406136143"
    },
    {
      "line": 119,
      "relation": "regulates",
      "evidence": "Ivermectin is an example of a positive allosteric effector that modiﬁes the pharmacological profile of the α7 nAChR.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 19,
      "target": 65,
      "key": "87d3fed32db527aa726e392fd99011ec413599ea5fccf9b7df70d713c90cbc6fb182860e851d2c4013e4f436c45fc4b6def2e50fa123486b7a5624fc7142e17f"
    },
    {
      "relation": "hasComponent",
      "source": 52,
      "target": 0,
      "key": "f045e610ca236366bea892f0ae0f9ab976b99ec9b239edcd9b1ebfe359628172535598fe967f55064cde6bfa84b605fd99f64ae2681c85c8afb409e8353bd050"
    },
    {
      "relation": "hasComponent",
      "source": 52,
      "target": 19,
      "key": "76a759b25bc0acc1ed36032cbecb8f7150488837e42f76932adba9124e33d2bce384e56e4bfe3930359234307c430b3f8f3cfa98e9128257cf4f7bae6bd76d3c"
    },
    {
      "line": 122,
      "relation": "increases",
      "evidence": "Dimethylphenylpiperazidium (DMPP) normally is a partial agonist at this receptor subtype, but it becomes almost a full agonist following ivermectin exposure (68).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 52,
      "target": 65,
      "key": "e46f99a2bbc23145e8eb5d62e65b3a9fe639a5dec90002889ffd3c8509612812d0f55ad6aab140083140525c0de2af5753cf461ccba75db582a7c463d9abd735"
    },
    {
      "relation": "hasComponent",
      "source": 53,
      "target": 2,
      "key": "af572d08ea0a99416563e6b4bf02e3ca0fdef7e44c92669eea2c64404f7611a15989925cca459d0deade5a294f7ccbb570aa856527084b1b3db0a554ca89f132"
    },
    {
      "relation": "hasComponent",
      "source": 53,
      "target": 14,
      "key": "602ff8def8a13dfd99eb5d781a2b77645f4bc38f4a75fbbcf1b319a36c1de36872d9025d023041d66ad07d7394466547bec87a5818ccf2485af3af77268f8650"
    },
    {
      "line": 125,
      "relation": "increases",
      "evidence": "5-Hydroxy-indol (5-HI) allosterically increases the α7 ACh-induced responses without modifying the response time course or sensitivity to the agonist (69).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 53,
      "target": 65,
      "key": "52e2330afe2dfaf95c9a4ff1715933dba3211a2582788ed149df646fa76340aca017ef14011f28007125d74e2684847ccec327ba4bd719fd380f02a912aa444d"
    },
    {
      "line": 128,
      "relation": "regulates",
      "evidence": "Another allosteric effector, 1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl)-urea (PNU-120596), dramatically modiﬁes the response time course, ampliude of the current, and agonist sensitivity of the rat and human α7 nAChRs (70).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 1,
      "target": 65,
      "key": "d30e47fd2549d4da1eadb49c4952c69af277df86d743008097ed742574b00e4a6a85de1cffadf8ff03e870aab71a01f02717aad820fc5c3571d6da33a0e8a2f9"
    },
    {
      "line": 131,
      "relation": "decreases",
      "evidence": "Dephosphorylation of the α7 receptor by genistein causes a signiﬁcant increase of ACh-evoked responses without modifying the response time course or ACh sensitivity (71, 72).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 18,
      "target": 66,
      "key": "90c07e47f5e94875f33d3da875ca24d181ec40479eb6b510346a18a1e225d0b4a89b066e236ed84269dde6546cae29a3da75b92984a9c191efd426292e313df5"
    },
    {
      "line": 135,
      "relation": "causesNoChange",
      "evidence": "Results show that genistein does not alter the surface expression of nAChRs, but rather it modiﬁes nAChRs in the cell membrane (71).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "cell surface"
          }
        }
      },
      "source": 18,
      "target": 60,
      "key": "010fb23ccb52217f05877b523334758fdf5ebda2786492ce72b30223db6552724dc13956db7be573597f07e79aceebeb70940b4aa59458685d0ff0105cb326e9"
    },
    {
      "line": 137,
      "relation": "regulates",
      "evidence": "Results show that genistein does not alter the surface expression of nAChRs, but rather it modiﬁes nAChRs in the cell membrane (71).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cell Membrane": true
        }
      },
      "source": 18,
      "target": 60,
      "key": "75ca95bb3ec2aa3c64c4baf0fc4c3dea08a113c2dba790879316de4e4fe09536b0ec3a51ca8ea7760f3bd038e32ad5ca3d5c206cf78bc0d40291a9f54ae92a67"
    },
    {
      "line": 132,
      "relation": "decreases",
      "evidence": "Dephosphorylation of the α7 receptor by genistein causes a signiﬁcant increase of ACh-evoked responses without modifying the response time course or ACh sensitivity (71, 72).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 66,
      "target": 65,
      "key": "a893f7ad243b502ad4345bd6cfd87797b0688d4ace01ba8237bfcc3ecb8f4488c9eb630b16ff4ba39a21e7ccf9386671f42cfb5ec70ca3f3ba19232100792042"
    },
    {
      "line": 142,
      "relation": "increases",
      "evidence": "Furthermore, Src-family kinases (SFKs) directly phosphorylate the cytoplasmic loop of α7 nAChRs in the plasma membrane.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cell Membrane": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "name": "kin",
          "namespace": "bel"
        }
      },
      "source": 61,
      "target": 66,
      "key": "165ca8382856bfaaf51d7554550a1d0df29d0622c87984a3b24b1d9edfc1fbe934fac43adffab3eef9345f86e876e8552e5d655e48b1a2fe63d964b252f7e4da"
    },
    {
      "line": 151,
      "relation": "increases",
      "evidence": "Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 10,
      "target": 14,
      "key": "0a8405e47cb60d8967e878f9a59cc7844407262136e28b3d56e1972a5048aae2a3215b7e04767d76cbc98bd2383c973d4c94ddf980f23d35ca0b6a402c928439"
    },
    {
      "line": 152,
      "relation": "increases",
      "evidence": "Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 10,
      "target": 16,
      "key": "c1f6a57475735c83466045b0e6c8b989c6949af41c170168cb20b22f28ed6538b665659dcd0381bddffbe7f5143058456de17566f045271c73bad0516a1849ae"
    },
    {
      "line": 153,
      "relation": "increases",
      "evidence": "Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 10,
      "target": 21,
      "key": "ca1b153639c5f8c0ed3547a4947a7f867f70fca53a2d174ba803cb556268c6b942fdb61c72e30476514b35ad989cb1e563d6956a68d37f75b4d1cb1a2b3d919a"
    },
    {
      "line": 154,
      "relation": "increases",
      "evidence": "Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 10,
      "target": 22,
      "key": "75b3c76ad096bbb21e68e431f89b2663026175b63e218f8e245f046d6b18596d159f3535e634fad340a17214f45044f8a318847e32fca37177f455b503fd3be9"
    },
    {
      "line": 155,
      "relation": "increases",
      "evidence": "Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 10,
      "target": 9,
      "key": "558d0eb39894409f3346a2ee48194d53c6bc156d0483b0b8dd34d09e510c79468c98e447ea87b4c84ad6705395af4e8e5344e3665d488165668a225e17a2bf57"
    },
    {
      "line": 156,
      "relation": "increases",
      "evidence": "Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 10,
      "target": 8,
      "key": "24e1cd89a684d2602ecbd6b16e3c9a5e0f35354c58b5d4057a612325f6dea8a48a61cb96f55cdef13d3ea86ed0bb732ffef29569ae2d51ab2138e3b07713f14d"
    },
    {
      "line": 299,
      "relation": "increases",
      "evidence": "In general, nicotinic agonists improve certain forms of memory, and nicotinic antagonists and cholinergic lesions impair memory (5, 141–145).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 10,
      "target": 48,
      "key": "1cf02c5d2f647cbf7e00b6f42b4f0f57598f5d5008f19e2e07f9032a839871754f33ad1d5a912df67f20341c31cdd6c40e05929d09b6fca7f3906c7629328154"
    },
    {
      "line": 315,
      "relation": "increases",
      "evidence": "In animal studies, acute and chronic nicotine administration improves working memory, and nicotinic agonists were found to improve learning and memory in humans and nonhuman primates (145).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 10,
      "target": 48,
      "key": "b4a55ee52da7f12f4d7bd662c335cfe63b5ac706e7cc2528277c5bb25ac13fc596ffed516934d3bc8ea9fd5e72e26efd10f8d48e6b419b9e82ee17c8a20e050e"
    },
    {
      "line": 314,
      "relation": "increases",
      "evidence": "In animal studies, acute and chronic nicotine administration improves working memory, and nicotinic agonists were found to improve learning and memory in humans and nonhuman primates (145).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 10,
      "target": 47,
      "key": "18dd537c2bbe9b30b7e9b76385d4129c61e62e13a59b862f6bdb2f09e2251aa63ec6eaa22165f36a8e962468faf8b8c79c4f1d8fd96342572cc5efb48b3df33d"
    },
    {
      "line": 320,
      "relation": "increases",
      "evidence": "During attention tasks, the nicotinic antagonist, mecamylamine, impaired accuracy or reaction time (151, 152) and nicotinic agonists improved accuracy (153). ",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 10,
      "target": 81,
      "key": "846f8a1d13418f42edd66270883320fae95578237657d2bd9e051f507f39b6edf37300d9a793f76ed9d8d3d687242d4f48daa8a1cfd2ad87cd75b8b7a49bfc3a"
    },
    {
      "line": 346,
      "relation": "increases",
      "evidence": "Consistent with these treatments, nicotinic agents improve cognitive deﬁcits of AD patients (20, 158).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 10,
      "target": 46,
      "key": "d35f73f27f5750a214c1f26ab8bec59cc82717007454ae0cb338fdd81d6fa57dae4e81f83d71d6f49b81ad60606c6a8053627658434126da1c7fb6f36a355c1e"
    },
    {
      "line": 275,
      "relation": "increases",
      "evidence": " The combination of enhanced glutamatergic release and strong postsynaptic response produces LTP of the glutamatergic afferents.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Cell": {
          "glutamatergic neuron": true
        }
      },
      "subject": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 9,
      "target": 34,
      "key": "eff6d7dece900cf7690fcae798053eb9c1751f96f8afbbff78636ddc95f3e801f4f26d14cfc08709768a80483b52cf75bfd0bf5f63a7b2a29527d7c705d44cb2"
    },
    {
      "line": 157,
      "relation": "decreases",
      "evidence": "Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 11,
      "target": 14,
      "key": "0db5900bd3a4b1e919209e3959531f1a4b8de4d2081035ac957824c2b2dd963a9a7ea15e331e123be6af4d2c9b0823fb25bee4645b07b0a71b6cc44027ff0fd2"
    },
    {
      "line": 158,
      "relation": "decreases",
      "evidence": "Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 11,
      "target": 16,
      "key": "540149b5411d7f87cdd17ee4c4d4761785131722384ff32bfd6b6ef7aef1ff821b75cb78901ec72289db3352ed79761c7117b729e872d73621a960b35baa6e9d"
    },
    {
      "line": 159,
      "relation": "decreases",
      "evidence": "Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 11,
      "target": 21,
      "key": "b6c5396344abeae494009b0bd795cae2297673e34d1b5180bca46448816f94abfd9c33effe32c4e12e637ccf7e0f0f7516facb02c84cb2e4d81efe00e3821b1c"
    },
    {
      "line": 160,
      "relation": "decreases",
      "evidence": "Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 11,
      "target": 22,
      "key": "1690fb3a4272185076ab268a045ce78746b9d1d60ef6d9253db3336f1bbed52e416d28d0f6286a3ea515c6f681f54b18f629e12377c39b4afbf1205c3c1aec1d"
    },
    {
      "line": 161,
      "relation": "decreases",
      "evidence": "Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 11,
      "target": 9,
      "key": "e9cfc72f15b678a4841275c864414b36b00f3a27bee67fb9fcc57210b89db87ff905402b3ecb3e31fa746bb8a4e45faa7d71e695359dd97aa6ae26f066f41c9a"
    },
    {
      "line": 162,
      "relation": "decreases",
      "evidence": "Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 11,
      "target": 8,
      "key": "5a7585a03586ddc4ab2a88fd055385ba17b3dd0114626a9393a3b0419854b0b38b9626ea04dfddca1a725e321076f4e37e0631054b512980cd95fa11490553cd"
    },
    {
      "line": 300,
      "relation": "decreases",
      "evidence": "In general, nicotinic agonists improve certain forms of memory, and nicotinic antagonists and cholinergic lesions impair memory (5, 141–145).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 11,
      "target": 48,
      "key": "f01ea3ccc702fb23235714867d426da0249828bcbcb7551809c210259d1d029045cf079f01605677592ad9a5e845ece440845d13632942a56955971ad3ada884"
    },
    {
      "line": 190,
      "relation": "decreases",
      "evidence": "This effect of preterminal nAChRs is inhibited by tetrodotoxin, which blocks sodium channels and, thus, prevents the regenerative voltage-dependent activation of calcium channels in the presynaptic bouton.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Presynaptic Terminals": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 23,
      "target": 50,
      "key": "54c0e52304af1456108cdba224bac0a158985d235200c305caae009ef3514b30c0c05e5fa72ea182544caf42e080102ffefb9a9ad14e9be8105f47bc161d014d"
    },
    {
      "line": 237,
      "relation": "association",
      "evidence": "Acting through these excitatory and inhibitory inputs and nAChRs located on the DA neurons, nicotinic receptors inﬂuence the ﬁring modes and ﬁring frequency of DA neurons (119, 121).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Dendrites": true,
          "Neocortex": true
        },
        "Cell": {
          "midbrain dopaminergic neuron": true
        }
      },
      "source": 40,
      "target": 60,
      "key": "6b8fada645e4af50709011b1f433f503a30d6a855a6c5cc6338f5690d6993cc2acdfc740b67774fc25ebcb4c017d4fa16b4ae1467dc30a8fa7ecc6141adf7766"
    },
    {
      "line": 215,
      "relation": "increases",
      "evidence": "In the rat CA3 region, spontaneous activation of GABA A receptors produces giant depolarizing potentials, whose frequency is controlled by α7∗ and non-α7 nAChRs.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 49,
      "target": 35,
      "key": "10149b0eab2f64ab8ee1b83243b4c6f738351b8b71bd94b547da1d7563b59ca661f0971858b648b33a06cefbf74cb03f8884a7b2af7929d52dfdd93973508b5d"
    },
    {
      "line": 226,
      "relation": "increases",
      "evidence": "Activation and desensitization of nAChRs by bath-applied nicotine also increases LTD induced by a stimulus train",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 20,
      "target": 60,
      "key": "ab009dae0f9ff6387379b90f2cb195bf80b23501560ba8c243a6ae6348ea4430a0699ea8d08c214ce871bd01d4aa9ce6ef496772d355fdb2b5fb0eee705cb417"
    },
    {
      "line": 251,
      "relation": "increases",
      "evidence": "The nicotine initially activates nAChRs on DA neurons, causing an increase in burst ﬁring and overall ﬁring rate (88, 121, 123, 124, 134).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Cell": {
          "dopaminergic neuron": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 20,
      "target": 60,
      "key": "2b662602f26dc1f29093c16f51b35be721c8b4d3bbf0bacb7df77dac6b39fd7b86587eae17fa94dfc55c178e1e7a53951bb446dd1cd1739c4a3ec7904ae1bcdc"
    },
    {
      "line": 245,
      "relation": "decreases",
      "evidence": "Nicotine decreases tonic DA release in the striatum that is evoked by single action potentials (127), and nicotine also alters the frequency dependence of DA release that is electrically evoked by stimulus trains (130, 131).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Corpus Striatum": true
        },
        "Cell": {
          "neuron": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 20,
      "target": 16,
      "key": "b901573383499dbed3ea3f932f38a8fc68d241bcc7e8d3230ccb39f712e0f2c74516f92dd99c37cd326729e5cc9b72c114c2ff5db37ba6e3619e90e07084726f"
    },
    {
      "line": 257,
      "relation": "increases",
      "evidence": "Simultaneously, nicotine activates presynaptic α7∗ nAChRs, boosting glutamatergic synaptic transmission onto DA neurons (23, 88, 123, 134).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Presynaptic Terminals": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 20,
      "target": 65,
      "key": "319994d3c053fa0dfa5163b0a800bd211987ff9ba508ae0c62eb72dbd1a02702161f59fb518febc5994d4cfce4645f8a3bd54cf062b1076d85e597033ba38623"
    },
    {
      "line": 313,
      "relation": "increases",
      "evidence": "In animal studies, acute and chronic nicotine administration improves working memory, and nicotinic agonists were found to improve learning and memory in humans and nonhuman primates (145).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 20,
      "target": 48,
      "key": "3d4d30555708c400f85a4ecbcfeb3f63fbf40955aba174ff75d44f66726e27bc2ba93108f15690d24e812257b4902b446c972812e5ae6ea719569a0ed45cc841"
    },
    {
      "line": 383,
      "relation": "increases",
      "evidence": " Moreover, although nicotine increases wakefulness in wild-type mice, it does not affect β2−/− mice. Overall, stimulation of nAChRs promotes arousal and REM sleep.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Epilepsy": true
        }
      },
      "source": 20,
      "target": 30,
      "key": "c02047893445cd970eaffba67de9a1a3bb8266e3f4a52f4f26cd1ebdf52874e7a0e429ea43984b0ff20bf7bb78b80f5cc170cd381de308b2b179d463af19d1ce"
    },
    {
      "line": 238,
      "relation": "association",
      "evidence": "Acting through these excitatory and inhibitory inputs and nAChRs located on the DA neurons, nicotinic receptors inﬂuence the ﬁring modes and ﬁring frequency of DA neurons (119, 121).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Dendrites": true,
          "Neocortex": true
        },
        "Cell": {
          "midbrain dopaminergic neuron": true
        }
      },
      "source": 39,
      "target": 60,
      "key": "c590d95820fd966ca5b45e4204a5b3551c6aa62b4acca23d07a29e5c44e12443481dc9206ab2b4f6d495d3ab41b44b539b09a87622a6729b22bf175c5d998c88"
    },
    {
      "line": 244,
      "relation": "increases",
      "evidence": "Nicotine decreases tonic DA release in the striatum that is evoked by single action potentials (127), and nicotine also alters the frequency dependence of DA release that is electrically evoked by stimulus trains (130, 131).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Corpus Striatum": true
        },
        "Cell": {
          "neuron": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 28,
      "target": 16,
      "key": "77d03d8c28374fa131f9ec2730da4639ce1b162f71f227662cd2c5990c1fa7c784798d04a1a56c91b610b7f3c05b4cad129ba1b44aa132303178a68f65f24341"
    },
    {
      "line": 266,
      "relation": "increases",
      "evidence": "Postsynaptic β2∗ nAChRs initially depolarize DA neurons, causing them to ﬁre action potentials while presynaptic α7∗ nAChRs boost glutamate release. ",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Cell": {
          "dopaminergic neuron": true
        },
        "MeSHAnatomy": {
          "Post-Synaptic Density": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 69,
      "target": 31,
      "key": "842a7fdbdbfe380bcc978c2f88e7417fc18d6be4c38ca93ef33564ff4cf34eac72bd9d081346daeb1ea502ae0b0605facb1ecf7168262d0749c46fafa7000328"
    },
    {
      "line": 267,
      "relation": "increases",
      "evidence": "Postsynaptic β2∗ nAChRs initially depolarize DA neurons, causing them to ﬁre action potentials while presynaptic α7∗ nAChRs boost glutamate release. ",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Cell": {
          "dopaminergic neuron": true
        },
        "MeSHAnatomy": {
          "Post-Synaptic Density": true
        }
      },
      "source": 31,
      "target": 40,
      "key": "7b8dcbe3f377cede98acf11afeade26d62ceb146b57d6260e566e54e45ebcc925ddcbb7d18bb54cd6ded4bb633e486612df584cfe5589add2e520470d3178c00"
    },
    {
      "line": 276,
      "relation": "increases",
      "evidence": " The combination of enhanced glutamatergic release and strong postsynaptic response produces LTP of the glutamatergic afferents.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Cell": {
          "glutamatergic neuron": true
        }
      },
      "source": 31,
      "target": 34,
      "key": "045f939ba007e9dcd5413a79e748a25864ba3173f4103f9a14c56f2fa2d2f73e5fa48cc6760f848257e0dcbe6d5343611a8a92a62f0d8ccfdb36c169aff5d3a1"
    },
    {
      "line": 281,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 77,
      "target": 60,
      "key": "5b0e12d804a6339403b9930ad40a276da34892758085a5ed42af2eef09b730ccd0c97c98776d1f8406860e3bf36df6878e62fabeb1928c46d0fa11097d435ff4"
    },
    {
      "line": 286,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 77,
      "target": 60,
      "key": "c74a588ba6289e97ae32a68237573f60c026d2a3e2e0e986c614c48e625707df66db6acd40c797549f7b3a9207cd1e5dc7909e5251d090ffbd58bd03ea69480c"
    },
    {
      "line": 282,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 76,
      "target": 60,
      "key": "7c8428f6a85fb0502bcfddc80e4de2b3dd9f292fd21b083b59e33cae5ee30b8786da1cb869a363910316554cdbcf788dd422a522614ab2c980423dde4c7d44c3"
    },
    {
      "line": 287,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 76,
      "target": 60,
      "key": "920dcd983f8cdc6001060866d068e098909d4658a25a206364307cae72df6c0bf9e2d58f47ae3e2278cfbf541c3cb1f0720e2f0fec9d2d0c83ea6616bb3200fe"
    },
    {
      "line": 284,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 78,
      "target": 60,
      "key": "05215b9077a0dc64b77d43384d6dda5fa0f2913928a7632e83f33ffd8a52db81305ddb7342b3c2ab5135cc4081f7cc248e5fce3b3f0de0983c8e85b63c9776e2"
    },
    {
      "line": 289,
      "relation": "negativeCorrelation",
      "evidence": "Nicotinic mechanisms contribute to cognitive function, and the decline of nicotinic mechanisms or loss of nAChRs has been observed in AD, dementia with Lewy bodies, Down syndrome, autism, and Parkinson’s disease (20, 140).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 78,
      "target": 60,
      "key": "667c6adaae53b8db7573e05e61f3081e31bc4ed6c58ac7393536c7b1c7c35470e32ad756cce0f767076c4e9060b9b7eb4037c0e566fc4c0d381ac9181a4ddd1f"
    },
    {
      "line": 294,
      "relation": "association",
      "evidence": "Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 42,
      "target": 60,
      "key": "418fc4e19193458c6fa28d7e3684ff0ff9059df113928c6d4e296768eb69add61df38c471c1f911245f1b7325721ee7299daa779c6849e717950c32485bc3a79"
    },
    {
      "line": 295,
      "relation": "association",
      "evidence": "Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 79,
      "target": 60,
      "key": "c38b57d4b3fa131e27daae36dbc52994fcf2919dfeb88d565dea5bab19cbda528022f0f2310dbf0ce687b6f48f6ac1d8200eb195b3f2e91bc95e3b15b1f56289"
    },
    {
      "line": 296,
      "relation": "association",
      "evidence": "Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression.",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 82,
      "target": 60,
      "key": "0c27eddb281bc4bdef8aeb1881c8798db1551ba47614b6ff5ae54f13c4120caa277944efb42d802f92b2cd6bb1e63e0d0257f2fc8986e28fd9d136993282cc95"
    },
    {
      "line": 305,
      "relation": "decreases",
      "evidence": "For example, local infusion of the α7 antagonist, methyllycaconitine (MLA), or the β2∗ antagonist, dihydro-β-erythroidine (DHβE), into the basolateral amygdala, the ventral hippocampus, or the dorsal hippocampus impairs the working memory of rats seeking food reward within a 16-arm radial maze (146–148).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "MeSHAnatomy": {
          "Amygdala": true,
          "Hippocampus": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 27,
      "target": 65,
      "key": "a2cea8b9ec79b7a2d7112dfa9adfc6c070acc1c00be7130bec4d0a1535945f46f25d173950ee49bfb2723dac01c641d9f2fde633a9b0154493b057c788f219ed"
    },
    {
      "line": 306,
      "relation": "decreases",
      "evidence": "For example, local infusion of the α7 antagonist, methyllycaconitine (MLA), or the β2∗ antagonist, dihydro-β-erythroidine (DHβE), into the basolateral amygdala, the ventral hippocampus, or the dorsal hippocampus impairs the working memory of rats seeking food reward within a 16-arm radial maze (146–148).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "MeSHAnatomy": {
          "Amygdala": true,
          "Hippocampus": true
        }
      },
      "source": 27,
      "target": 48,
      "key": "349e611b79132743f2e2168d15f6ae0697dbb0751039429b902c83f968bb37f1bc33bc56d40f46ba102c6c8efb9a2c09a19b5ac7950867a455f717592e7a06c9"
    },
    {
      "line": 307,
      "relation": "decreases",
      "evidence": "For example, local infusion of the α7 antagonist, methyllycaconitine (MLA), or the β2∗ antagonist, dihydro-β-erythroidine (DHβE), into the basolateral amygdala, the ventral hippocampus, or the dorsal hippocampus impairs the working memory of rats seeking food reward within a 16-arm radial maze (146–148).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "MeSHAnatomy": {
          "Amygdala": true,
          "Hippocampus": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 69,
      "key": "088700138fb115f234bf38963e525a6240769854d6597fe41a324339bf53e32787cbf07e914c9f279fcd82e483853fb2f9571c1c1252db24042cdecf832ff96e"
    },
    {
      "line": 308,
      "relation": "decreases",
      "evidence": "For example, local infusion of the α7 antagonist, methyllycaconitine (MLA), or the β2∗ antagonist, dihydro-β-erythroidine (DHβE), into the basolateral amygdala, the ventral hippocampus, or the dorsal hippocampus impairs the working memory of rats seeking food reward within a 16-arm radial maze (146–148).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "Species": {
          "10116": true
        },
        "MeSHAnatomy": {
          "Amygdala": true,
          "Hippocampus": true
        }
      },
      "source": 7,
      "target": 48,
      "key": "6b95499793535f7924c99067c478e8df1f58d434a570b8ff2899112735972ce0cc72c951c642bf3c6dc384b025838e67c87a93e45704f8b68b18dc852483cefb"
    },
    {
      "line": 318,
      "relation": "isA",
      "evidence": "During attention tasks, the nicotinic antagonist, mecamylamine, impaired accuracy or reaction time (151, 152) and nicotinic agonists improved accuracy (153). ",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 12,
      "target": 11,
      "key": "f4bb31f1e8898b4189d7df30b1384478902a21dcbd4642a1a9f1cf6653c6a3a5ad183d3339eb3d346c9f38fded6792ef7a135a3d3339dcb75f5cda64321eb105"
    },
    {
      "line": 319,
      "relation": "decreases",
      "evidence": "During attention tasks, the nicotinic antagonist, mecamylamine, impaired accuracy or reaction time (151, 152) and nicotinic agonists improved accuracy (153). ",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "source": 12,
      "target": 81,
      "key": "ebcf812a7e5d19f918544e0548874ca1c51e05a4cd757d5e3e93f3400e1a9496a980274f2234b195839d6a7f7e92aebfa5cbac11bacd5a3a1a759a9fe5c5afde"
    },
    {
      "line": 326,
      "relation": "positiveCorrelation",
      "evidence": "The most well-appreciated neuronal loss, however, is in the cholinergic system (155, 156), particularly the basal forebrain cholinergic system comprised of the medial septal nucleus, the horizontal and vertical diagonal bands of Broca, and the nucleus basalis of Meynert (157).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Cell": {
          "cholinergic neuron": true
        }
      },
      "source": 36,
      "target": 72,
      "key": "b146213d588d5b436976727844fa8ad3449f84c75a539376be9607eefd67feeee59df3586731e91d58de26d7488d39375700d37c2b0aac1e6172e04d69cc4b83"
    },
    {
      "line": 332,
      "relation": "positiveCorrelation",
      "evidence": "As AD worsens, cholinergic neurons are progressively lost and the number of nAChRs declines, particularly in the hippocampus and cortex (140, 158).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "Cell": {
          "cholinergic neuron": true
        }
      },
      "source": 36,
      "target": 72,
      "key": "130ff789b23b7ad11d2086f78457b64bae587b9db248b2dea06f8b9d59e5d1176b2199a5bc07df52321dae2f48fa65054fbab30823e365650142e4b11e0089ec"
    },
    {
      "line": 338,
      "relation": "decreases",
      "evidence": "The most commonly prescribed treatments for AD are acetylcholinesterase inhibitors, which decrease the hydrolysis rate of ACh and, thereby, enhance cholinergic signaling. One such drug, galantamine (Reminyl\u0002), also potentiates nAChRs (66).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 3,
      "target": 72,
      "key": "af756b77a97c9b4ed4a1ec2a7cf3fad32b10aa916ad6cfc4c83c71b82757bbd3e66d9934df829c30067ccc449a6d7e2df4702f1646337d9983e7652adcc44d77"
    },
    {
      "line": 339,
      "relation": "decreases",
      "evidence": "The most commonly prescribed treatments for AD are acetylcholinesterase inhibitors, which decrease the hydrolysis rate of ACh and, thereby, enhance cholinergic signaling. One such drug, galantamine (Reminyl\u0002), also potentiates nAChRs (66).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 62,
      "key": "c560eec523fdca7543411c5fc78cc84637f9b048d031790429bf6d540811aef1209691403dd69be1da522286cdf5b3365d1c34d939a11925826272ac31e31c51"
    },
    {
      "line": 340,
      "relation": "decreases",
      "evidence": "The most commonly prescribed treatments for AD are acetylcholinesterase inhibitors, which decrease the hydrolysis rate of ACh and, thereby, enhance cholinergic signaling. One such drug, galantamine (Reminyl\u0002), also potentiates nAChRs (66).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 3,
      "target": 85,
      "key": "77dc563ddda9d401c1470230f3cdc6e44ce1c2fda55a152dbde29f8e764a3d4550a5a9e6ee9784058867f489e2aeece99865de89ac5b9f31e350967d467b6481"
    },
    {
      "line": 341,
      "relation": "increases",
      "evidence": "The most commonly prescribed treatments for AD are acetylcholinesterase inhibitors, which decrease the hydrolysis rate of ACh and, thereby, enhance cholinergic signaling. One such drug, galantamine (Reminyl\u0002), also potentiates nAChRs (66).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 60,
      "key": "bd28b43cb3b37983f389c4cdd62dda9bda89dcaeb153fba958d1c14857ed7cbcb3688f1655dcaaf1adc49f41c15b7685aed53b7bfa801355f145d11e6fa0d72e"
    },
    {
      "line": 342,
      "relation": "isA",
      "evidence": "The most commonly prescribed treatments for AD are acetylcholinesterase inhibitors, which decrease the hydrolysis rate of ACh and, thereby, enhance cholinergic signaling. One such drug, galantamine (Reminyl\u0002), also potentiates nAChRs (66).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 17,
      "target": 3,
      "key": "b51b7ac8d46c0adcdd931e2721da8c6a0915f8293b5edd7047f31b17ba2a8387f94320c64b4b920b421260e8d9ef7c2181e9834565a6b9fd4ab387fb5920e429"
    },
    {
      "line": 343,
      "relation": "increases",
      "evidence": "The most commonly prescribed treatments for AD are acetylcholinesterase inhibitors, which decrease the hydrolysis rate of ACh and, thereby, enhance cholinergic signaling. One such drug, galantamine (Reminyl\u0002), also potentiates nAChRs (66).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 17,
      "target": 60,
      "key": "9b151e6248dd538625a47f81616765ce7fc581915d4f9e0f354b2c6c1937dbfd3d3bbfd68cb65a0d19a451dc5af4518aba807582ba9a1905704ae49f69ec3492"
    },
    {
      "line": 350,
      "relation": "decreases",
      "evidence": "Although Aβ peptides negatively alter the cholinergic system at multiple sites, including ACh synthesis, ACh release, and muscarinic receptors (157), the discovery that Aβ1−42 binds to α7 nAChRs with high afﬁnity suggested the potential for a causal role of nAChRs in AD (159, 160).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 5,
      "target": 14,
      "key": "a6cf8559a6e57b44398150790d340355406e316b89044d83e9ccd3fcd71abe7be29be3ac8fdf3dfafc5f4de2fd307df248ee37959704e72a0dfee19154b97a0c"
    },
    {
      "line": 351,
      "relation": "decreases",
      "evidence": "Although Aβ peptides negatively alter the cholinergic system at multiple sites, including ACh synthesis, ACh release, and muscarinic receptors (157), the discovery that Aβ1−42 binds to α7 nAChRs with high afﬁnity suggested the potential for a causal role of nAChRs in AD (159, 160).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 5,
      "target": 14,
      "key": "dccd128aa333f863e1f42c847af8be195c5cc57a074776e7641c5a7c5c0b9a70db7686d53fd0b54016b4e417ec09284eb524b7f67d76d96870769b6befe3b35d"
    },
    {
      "line": 352,
      "relation": "decreases",
      "evidence": "Although Aβ peptides negatively alter the cholinergic system at multiple sites, including ACh synthesis, ACh release, and muscarinic receptors (157), the discovery that Aβ1−42 binds to α7 nAChRs with high afﬁnity suggested the potential for a causal role of nAChRs in AD (159, 160).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 5,
      "target": 59,
      "key": "e24951c15e03f8efc70bb06084aa6299f035f5c8be328d117feeaf73244a53b9216c4eb3eec1a330053b3d1eae6d1a61f45e2d9fd37810f69b50e9537e3e9819"
    },
    {
      "line": 360,
      "relation": "positiveCorrelation",
      "evidence": "This prospect was supported by the finding that α7 nAChRs were found in plaques (159), and α7 and α4 subunits positively correlated with neurons that accumulated Aβ and hyperphosphorylated tau in AD brain tissue (161).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Cell": {
          "neuron": true
        }
      },
      "source": 5,
      "target": 65,
      "key": "731f46f17c1e03086847123f12ae1cf5ad99ba9ca6f3111583ac22c0fde09e73cda4fa90b1a29a1a95e77e48bb33dfc1a37516912347d39820da5def54e3e7bd"
    },
    {
      "line": 362,
      "relation": "positiveCorrelation",
      "evidence": "This prospect was supported by the finding that α7 nAChRs were found in plaques (159), and α7 and α4 subunits positively correlated with neurons that accumulated Aβ and hyperphosphorylated tau in AD brain tissue (161).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Cell": {
          "neuron": true
        }
      },
      "source": 5,
      "target": 63,
      "key": "03166ae303985944fc00f186b734ca7e0372b04ba8285d98b056c3dde0748c2840b52d036d75add3618bfc5cbede909245f7d986a49e1d8046fd5365e418738a"
    },
    {
      "relation": "hasComponent",
      "source": 51,
      "target": 4,
      "key": "1b84261bd7deee675dd680094aa1becb19f7501c64ae8c5aabef42796dbb78fd3994eb79d86551ee264afeecc9a14b7d68929cb29951d93b5191ea2027f83b95"
    },
    {
      "relation": "hasComponent",
      "source": 51,
      "target": 65,
      "key": "8fdf320ec4cc0aec22d9a738f0ef73234c990d528ca67438b31936b325c5730ca98f47f1cd2a7880ddf93f16593c8d85dce1aa9a8ee505dabef91ecc67d77c89"
    },
    {
      "line": 354,
      "relation": "association",
      "evidence": "Although Aβ peptides negatively alter the cholinergic system at multiple sites, including ACh synthesis, ACh release, and muscarinic receptors (157), the discovery that Aβ1−42 binds to α7 nAChRs with high afﬁnity suggested the potential for a causal role of nAChRs in AD (159, 160).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 51,
      "target": 72,
      "key": "2c6d8a308e419ef5645f95bf4879936635e03bc103560950d2aa8197d4dcf36fea557fba13838ce337bf8e9c5a2a1c6424809387865e15cc3b9ad551d8831253"
    },
    {
      "line": 357,
      "relation": "association",
      "evidence": "This prospect was supported by the finding that α7 nAChRs were found in plaques (159), and α7 and α4 subunits positively correlated with neurons that accumulated Aβ and hyperphosphorylated tau in AD brain tissue (161).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 24,
      "target": 65,
      "key": "33fb798c85142faa2efc671c46f5d6d08607f94cd2f68f9d1b76af7e301b8698f76f6dc9e6856e633a68bbc8dad62ef1d60b55e48ef51c58c1e24095435e0113"
    },
    {
      "line": 361,
      "relation": "positiveCorrelation",
      "evidence": "This prospect was supported by the finding that α7 nAChRs were found in plaques (159), and α7 and α4 subunits positively correlated with neurons that accumulated Aβ and hyperphosphorylated tau in AD brain tissue (161).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Cell": {
          "neuron": true
        }
      },
      "source": 71,
      "target": 65,
      "key": "c704c258c18f09b583541dcc7010686db22f9219f4c458b089b24ac2d6e2ed203ad1878190dac544f172b5a618f436fd5cd22f97cacb84254dc20af6e441aa23"
    },
    {
      "line": 363,
      "relation": "positiveCorrelation",
      "evidence": "This prospect was supported by the finding that α7 nAChRs were found in plaques (159), and α7 and α4 subunits positively correlated with neurons that accumulated Aβ and hyperphosphorylated tau in AD brain tissue (161).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Cell": {
          "neuron": true
        }
      },
      "source": 71,
      "target": 63,
      "key": "92c4bf708c26ecb8ca230aa647063231fe523d74ae036aefa1f10ce13766c7b28aeebf596fabfca5af90b712aae4a813b334d3486a509b517c76b0a559073d0b"
    },
    {
      "relation": "hasVariant",
      "source": 70,
      "target": 71,
      "key": "9fbd9218812f1cd82827e2d73f3b6af04acbe1f408aaedcdc53c6fc17a36272c67cdcc254874f5473ba4443fa19971fe4877420e735c04f4f7353480d8e1f8b2"
    },
    {
      "line": 362,
      "relation": "positiveCorrelation",
      "evidence": "This prospect was supported by the finding that α7 nAChRs were found in plaques (159), and α7 and α4 subunits positively correlated with neurons that accumulated Aβ and hyperphosphorylated tau in AD brain tissue (161).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Cell": {
          "neuron": true
        }
      },
      "source": 63,
      "target": 5,
      "key": "03017e4ec7417f29e559a73c232b9d9ea2a383f45227d4c8712ac6281059678f98b544110e8a8152ab4e89cba4107b99de6b6f02c3720831da1837435e0471f7"
    },
    {
      "line": 363,
      "relation": "positiveCorrelation",
      "evidence": "This prospect was supported by the finding that α7 nAChRs were found in plaques (159), and α7 and α4 subunits positively correlated with neurons that accumulated Aβ and hyperphosphorylated tau in AD brain tissue (161).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Cell": {
          "neuron": true
        }
      },
      "source": 63,
      "target": 71,
      "key": "e0b3f9f6b450d94c5590ffe095209d25f08601dbfea2ccb262e27e54c1be40127537d7e9b20f2cd9558b370a7b9417901eb88b4e5285c85ba268ae91a12b3e89"
    },
    {
      "relation": "hasVariant",
      "source": 63,
      "target": 64,
      "key": "6e2ce086835439030a1e338499e82755e6010a2267b53d971e015dc34d0d3fdcfc21a6e2435d32dd553e3d71e7afeb89e755fb6e97e6f7accf3c0785f593a2af"
    },
    {
      "line": 371,
      "relation": "increases",
      "evidence": "A mutation in the gene encoding the α4 nAChR subunit (CHRNA4) causes a genetically transmissible form of epilepsy, which was the ﬁrst discovery of a human disease associated with a neuronal nAChR (165, 166). The mutation has been identiﬁed as a single base substitution converting a serine into threonine (S248F) in the TM2 domain of the α4 subunit (165).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Epilepsy": true
        }
      },
      "source": 64,
      "target": 83,
      "key": "d0669e9143b60d4535695949eaea741641072e7322bf1696f3b7e944275b3f91ca304c25779ffa18d2f3c4a8e3dc1bfafb72f48ebfb1e674705c34219fd8a40e"
    },
    {
      "line": 374,
      "relation": "positiveCorrelation",
      "evidence": "Subsequent to the original discovery, several other families suffering from typical ADNFLE or nocturnal frontal lobe epilepsy (NFLE) have been found to have a mutation either in α4 or β2 (encoded by CHRNB2) (165, 166, 168–170).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Epilepsy": true
        }
      },
      "source": 56,
      "target": 74,
      "key": "b5671cb2a349b872f30401b3c1ec65e46e60e882beb9f9fff18cfb65c82b12ebf7c38de02c1e648a440e2cdf71f5262501da20b04a36a3dac17a213ad030908c"
    },
    {
      "relation": "hasVariant",
      "source": 55,
      "target": 56,
      "key": "a55453e032eb30006358dd2e325a54697be64ddeb66592a687130f220b5c82d280ac4f46f5c8d6610c696f8f08a57cce33a2a91e183f2660abb7f0e9f063837c"
    },
    {
      "line": 374,
      "relation": "positiveCorrelation",
      "evidence": "Subsequent to the original discovery, several other families suffering from typical ADNFLE or nocturnal frontal lobe epilepsy (NFLE) have been found to have a mutation either in α4 or β2 (encoded by CHRNB2) (165, 166, 168–170).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Epilepsy": true
        }
      },
      "source": 74,
      "target": 56,
      "key": "a53c11cefe2e2deab58437e6995e73e89650b8598690d257be027e69de3c7ca6b1ad22a397cf2b8a51240eab38b96a687e9f81f7872695f5c06cc14562384a1c"
    },
    {
      "line": 375,
      "relation": "positiveCorrelation",
      "evidence": "Subsequent to the original discovery, several other families suffering from typical ADNFLE or nocturnal frontal lobe epilepsy (NFLE) have been found to have a mutation either in α4 or β2 (encoded by CHRNB2) (165, 166, 168–170).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Epilepsy": true
        }
      },
      "source": 74,
      "target": 58,
      "key": "ab9c1bbd96721202c1990e636d1625d600073dab91d7ea1504fb74d04b6ef8a25e1d976b16419e8ca4b17c470701be4a6570c019c8f0fe119e51e14bed4ca745"
    },
    {
      "line": 375,
      "relation": "positiveCorrelation",
      "evidence": "Subsequent to the original discovery, several other families suffering from typical ADNFLE or nocturnal frontal lobe epilepsy (NFLE) have been found to have a mutation either in α4 or β2 (encoded by CHRNB2) (165, 166, 168–170).",
      "citation": {
        "type": "PubMed",
        "reference": "17009926"
      },
      "annotations": {
        "MeSHDisease": {
          "Epilepsy": true
        }
      },
      "source": 58,
      "target": 74,
      "key": "e3d7a1a42835ef6c3cce56aff65e087fab33e1ffd4ca194d7941a59ee102aba4edfd516f772fe6efed12df553a0592dbab7409849044b0cfb6c552f850bbde02"
    },
    {
      "relation": "hasVariant",
      "source": 57,
      "target": 58,
      "key": "e18a9775c8ea05210ff3d4eabbb65ed846e4e5b121e24ee7f5acdceb6f595d404d63173d346723cdda48ee9b6806b164db7f50a1952b255fa5fd1c17ac46a250"
    }
  ]
}